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Older age is associated with decline in many physiological functions that eventually lead 
to increased susceptibility to diseases. The rate of aging varies among individuals and may be 
influenced by genes. This dissertation has three aims: 1) define a measure of aging using 
physiologic traits and determine its heritability among various pedigree structures, 2) 
investigate genetic associations with the age trait using genome-wide association study 
analyses, and 3) focus on decline in kidney function by examining its association with known 
kidney loci and clinical risk factors within the SardiNIA Study on Aging. 
 Using data from five genetic cohorts (30,000+ individuals) with varying pedigree 
structure (SardiNIA Study on Aging – large pedigrees, Framingham Heart Study offspring – small 
xii 
 
pedigrees, Atherosclerotic Risk in Communities Study – unrelated, and two twins studies: 
Twingene and TwinsUK), two aging traits were developed. Both traits employ three physiologic 
health measures (kidney function, systolic blood pressure, and waist circumference) to estimate 
an individual’s biologic age and contrast it with actual age. Linear mixed modeling was 
employed to estimate a predicted age, while Cox models were used to estimate a risk age 
equivalent to the age of the census population with the same mortality risk.   
Using Merlin software (Abecasis, 2002), both age traits were found to be heritable in all 
cohorts with h2 estimates of 0.25 to 0.68, depending on pedigree structure. Meta-analysis 
revealed a genome-wide significant association (p < 5 x 10-8) within the LRP1B gene on 
chromosome 2.  LRP1B produces low density lipoprotein receptor-related protein 1B and has 
been previously associated with tumor suppression, metabolic traits, and successful aging.   
Association analyses were also conducted using a genetic risk score for CKD, adjusting 
for clinical factors, with CKD prevalence and change in kidney function. One additional allele in 
the genetic risk score for CKD was significantly associated with CKD prevalence (OR=1.07, 
p=0.001), decline in eGFR (β=-0.23, p=0.004), and eGFR decline > 1 SD (OR=1.05, p=0.04). 
These findings further our understanding of the genetics of aging and the CKD risk score 









The human population, not just its individuals, is aging. It is projected that by the year 
2016, for the first time in history, the proportion of individuals over the age of 65 years will 
surpass the proportion of children under the age of 5 years (Dobriansky, et.al., 2007). This 
population shift has happened for a few reasons. Life expectancy has increased. There has been 
a shift from high reproductive rates to low reproductive rates. There has been a shift from the 
predominance of infectious disease to non-communicable disease and chronic conditions as 
leading cause of death (Dobriansky, et.al., 2007).  
In 2012 the 10 leading causes of death in the US were:  heart disease (597,689 deaths), 
cancer (574,743 deaths), chronic lower respiratory diseases (138,080 deaths), 
stroke/cerebrovascular diseases (129,476 deaths), accidents/unintentional injuries (120,859 
deaths, Alzheimer's disease (83,494 deaths), diabetes (69,071 deaths), nephritis/nephrotic 
syndrome/nephrosis (50,476 deaths), influenza and pneumonia (50,097 deaths), and 




causes of death are chronic conditions, typically found among the elderly, while influenza and 
pneumonia, although infectious diseases, are also much more likely to be deadly among the 
elderly.  These US numbers are very reflective of the world-wide causes of death for middle and 
high income countries (World Health Organization, 2011).  Overall, five of the ten leading 
causes of death world-wide are chronic conditions and include:  ischaemic heart disease (7.25 
million deaths, 12.8%), stroke and other cerebrovascular disease (6.15 million deaths, 10.8%), 
chronic obstructive pulmonary disease (3.28 million deaths, 5.8%), trachea, bronchus, lung 
cancers (1.39 million deaths, 2.4%), and diabetes mellitus (1.26 million deaths, 2.2%); leaving 
the remaining five causes to communicable diseases (lower respiratory infections,  diarrheal 
diseases,  HIV/AIDS, and tuberculosis) or accidents (road traffic accidents). 
 While the current rates of these chronic conditions are high, they are projected to get 
even worse. The American Heart Association (AHA) projects that in the next 20 years, more 
than 40% of the US population is expected to have some form of cardiovascular disease. This 
increase will triple the total direct medical costs of caring for hypertension, coronary heart 
disease, heart failure, stroke, and other forms of cardiovascular disease from the current $273 
billion to more than $800 billion (Heidenreich PA, et.al, 2011). It is also predicted that the 
prevalence of cardiovascular disease will increase by approximately 10% over the next 20 years 
if there are no changes in prevention practices and treatment trends. The increase is likely to be 
even greater if some risk factors, such as diabetes and obesity, continue to increase rapidly. 
 The good news, though, is that heart disease is largely preventable and many believe 




et.al, 2011). Recent work from the Coronary Artery Risk Development in Young Adults (CARDIA) 
study suggests cardiovascular disease prevention should begin earlier in life, as many risk-factor 
levels in individuals younger than 30 years old were predictive of subclinical atherosclerosis 15 
years later. The data also suggests that modest improvements in risk factors earlier in life have 
a larger impact than more substantial reductions later in life (Lee DH, et.al, 2003). 
 A large contributor in many of the chronic conditions that are plaguing our society is 
obesity. Recent research has shown that obesity accelerates the aging of adipose tissue, a 
process only now beginning to come to light at the molecular level (Ahima, 2009). Evident of 
this has come from experiments conducted in mice which suggest that obesity increases the 
formation of reactive oxygen species in fat cells, shortens telomeres—and ultimately results in 
activation of the p53 tumor suppressor, inflammation and the promotion of insulin resistance.  
 Data from the National Health and Nutrition Examination Survey, 2009–2010 (Flegal, 
2012 and Ogden, 2012) show that more than 2 in 3 adults are considered to be overweight or 
obese, more than 1 in 3 adults are considered to be obese, with more than 1 in 20 adults 
considered to have extreme obesity. About one-third of children and adolescents ages 6 to 19 
are considered to be overweight or obese, and more than 1 in 6 children and adolescents ages 
6 to 19 are considered to be obese. 
The health risks of being overweight or obese include: type 2 diabetes, heart disease, 
high blood pressure, nonalcoholic fatty liver disease (excess fat and inflammation in the liver of 
people who drink little or no alcohol), osteoarthritis (a health problem causing pain, swelling, 




kidney), and stroke (Weight-control Information Network, 2012). Since the early 1960s, the 
prevalence of obesity among adults has more than doubled, increasing from 13.4 to 35.7 
percent in U.S. adults age 20 and older (Flegal, 2012 and Ogden, 2010). Obesity prevalence 
remained mostly stable from 1999 to 2010, but has increased slightly, yet in a statistically 
significant way, among men overall, as well as among black women and Mexican American 
women. Among children and adolescents, the prevalence of obesity also increased in the 1980s 
and 1990s but is now mostly stable at about 17 percent (Ogden, 2012). 
With rates of high blood pressure and diabetes on the rise, it is no surprise that kidney 
disease is also on the list of the leading causes of death in the US.  In the US kidney disease 
affects more than 20 million people, or approximately 7% of the US population (USRD, 2011). 
Rates of chronic kidney disease and end stage renal disease are increasing as our population of 
elderly is increasing. From 1991-2004, the prevalence of CKD has increased from 10% - 13% and 
the number of patients treated with dialysis or transplantation has increased from 209K to 
472K. In the period 1991-2001 ESRD incidence increased 43% (USRDS, 2011). 
 How can we reduce the burden of these chronic diseases on our society and improve 
the health of our elderly individuals? Just as the advances in public health over the past 100 
years have enabled a shift from infectious to chronic disease, we must now take steps to 
counter the effects of chronic disease on our aging population. Some public health researchers 
are working toward better educating our population on living healthier lifestyles, while others 
are working with the government to develop policies to improve overall health, and some are 




I believe Heidenreich, et.al, said it quite clearly in terms of the next steps for heart 
disease and his statement can be extended to many other chronic diseases of the elderly: "In 
the public-health arena, more evidence-based effective policy, combined with systems and 
environmental approaches, should be applied in the prevention, early detection, and 
management of cardiovascular disease risk factors. Through a combination of improved 
prevention of risk factors and treatment of established risk factors, the dire projection of the 
health and economic impact of cardiovascular disease can be diminished." (Heidenreich PA, 
et.al, 2011). The key to lowering the burden of chronic disease is to prevent the chronic 
diseases from occurring.  
In the current age of unequal medical coverage in the US, this will be a difficult task. 
Many individuals never visit a doctor unless they are already ill. Without getting into a political 
discussion of health care coverage or public health programs, it is clear that first, we must have 
people seen regularly starting at young ages by their health professionals. We need to be able 
to detect individuals at higher risk of developing these costly chronic conditions and intercede 
early in the process or before the course of the conditions begin. 
My current work toward this goal combines the use of statistical genetics and 
epidemiologic principles to better understand the role genetics plays in the aging process, 
focusing on quantitative measures for the three chronic conditions highlighted above: 
cardiovascular disease, obesity, and chronic kidney diesase. If we can recognize individuals at a 
higher risk of accelerated aging and at a higher risk of age-related diseases very early in life, 




preventative treatment. As the CARDIA study (Lee DH, et.al, 2003) has shown, early 
intervention may be the key. We need to take action before clinical symptoms appear. 
Although the use of genetics in medicine and public health is still in its infancy, it may be the 
key to identifying these high-risk individuals early. 
Another approach to improving chronic conditions is highlighted in recent research at 
the Mayo Clinic in the use genetics to better understand the pathophysiological process of 
aging to devise better treatments. This research has implicated a category of cells, known as 
senescent cells that promote aging in tissues (Baker, et.al, 2011). These cells accumulate in 
aging tissues, like arthritic knees, cataracts, and arterial plaque and cause damage by secreting 
agents that stimulate the immune system and cause low-level inflammation. There is hope that 
cleansing the body of these cells may postpone many of the diseases of aging. A possible 
mechanism for clearance involves a characteristic marker gene, p16Ink4a, which is switched on 
by the senescent cells, making many hopeful this finding will be clinically useful. 
Findings such as that of senescent cells are very exciting, because aging is such a 
complex process that it can be difficult to study. One challenge of investigating the genetics of 
aging, in particular, is in having a measure of aging that can be applied to living individuals of 
varying age. Many studies have focused on specifically studying centenarians (Sebastiani and 
Perls, 2012; Beekman, et.al, 2013), but these studies are often very small. Another approach 
has been to use age at death as a measure of aging, but again there are limitations, such as the 




I believe the key to making early prevention and intervention possible is having good 
early biomarkers and genetic markers available. Because the physical decline that accompanies 
aging typically involves multiple systems that often interact, such as the cardiovascular system 
and the renal system, the first goal of this dissertation (Chapter II) aims to develop a measure of 
aging, based on three easily measured physiologic traits: blood pressure, waist circumference, 
and serum creatinine. It was also important for this measure to be applicable to a wide range of 
ages and among individuals who are still living.   Two definitions of aging are explored. Both 
measures estimated a “biologic” age for each individual. The first measure accomplishes this by 
calculating a predicted age, while the other uses the individual’s risk of mortality to assign them 
a “risk” age which is equal to the age at which someone in the census population has the same 
mortality risk. Both measures are then compared to the person’s real age. In this way we can 
classify individuals as either being younger or older biologically than their actual age. 
These measures of aging can be used to identify new biomarkers or predictors of aging. 
If there is a genetic component to the traits, we would expect them to have a significant degree 
of heritability. Using four family-based cohort studies, with differing pedigree structures, 
heritability of both traits was explored. After confirming that both traits are moderately 
heritable in Chapter II, Chapter III contains a genome-wide association study (GWAS), 
incorporating an additional unrelated cohort of middle-aged individuals, and ultimately will 
contain genotype and phenotype data on over 30,000 individuals after replication. 
Based on evolutionary theories of aging and past research, expected findings from the 




antioxidant defense, and thus indirectly regulate longevity (Kirkwood, 2008). This is because 
aging has not been shown to be programmed, but rather results from accumulation of somatic 
damage, owing to limited investments in maintenance and repair. People may wonder how 
these deleterious variants have escaped natural selection. The two main theories are that the 
variants have late action late-acting deleterious effects, after the age where natural selection is 
greatest (sexual maturity) or that there is a trade-off between benefit at an early age against 
harm at older ages, termed antagonistic pleiotropy (Ness and Williams, 1996). 
Because kidney function is one of the best predictors of age and because of my personal 
interest in it from working on the Dialysis Outcomes and Practice Patterns Study (DOPPS) for 
over 10 years, Chapter IV of this dissertation focuses specifically on chronic kidney disease. As 
previously mentioned, the rates of CKD and ESRD are increasing all over the world. Mortality 
rates once a person reaches end-stage are over 20% per year. The key to improving these 
numbers is to keep patients from reaching ESRD.  
Over our lifetime, kidney function decreases for all individuals. Among healthy 
individuals, it has been reported that kidney function, measured as estimated glomerular 
filtration rate (eGFR), declines on average 0.4 – 1.2 ml/min/year after age 40 (Vlassara, et.al, 
2009). There are known clinical predictors of accelerated decline in kidney function, such as 
diabetes, hypertension, smoking, and family history. Recent studies, by such consortia as 
CKDGen (Köttgen, et.al, 2009 and Böger, et.al, 2011), have also determined several genetic loci 
that are predictive of kidney function. To examine the potential clinical and public health 




kidney function. The score is based on the reported loci from CKD-Gen significantly associated 
with eGFR and the prevalence kidney disease. This was accomplished by exploiting the 
longitudinal nature of the SardiNIA Study on Aging and examining the change in kidney function 
over time. 
Through this work, it is my hope to demonstrate the utility of incorporating the use of 
genetic information into clinical practice at an early stage may lead to improvements in chronic 
disease outcomes. While the clinical use of using genetic scores remains to be tested, they 
could potentiallly reduce the societal burden of care as well as improved survival and quality of 







Development of Two Measures of Aging and Assessment of Their 




When one thinks of aging, they commonly think of heart disease, cancer, and diseases 
such as Alzheimer’s, but these age-related pathologies are actually a side-effect of the human 
body’s loss or malfunction in cell processes. Also, unlike pathologies, aging occurs in every 
human given sufficient time (Hayflick, 2004). While gerontology studies age-related disease and 
degeneration, with the goals of preserving health and prolonging human life, it does not look at 
the fundamental causes of aging or predisposition for individuals to age at such variable rates. 
The fundamental cause of aging and its biological variation are rooted in the cellular and 
molecular mechanisms that are consequences of the interplay of environmental and genetic 
factors.  
Genetic studies have been conducted to better understand aging and assess its 
heritability. However, these have mainly focused on studying 1) longevity, using very selected 




populations (Frankowski, et.al., 2012; Osiewacz, et.al., 2013); or 3) specific age-related 
pathologies, such as cancer (Han, et.al, 2013). While these studies have identified genetic loci 
and chromosomal regions of interest, we do not know how generalizable animal studies are to 
human populations. Also, there hasn’t been replicated evidence of key genetic elements 
underlying aging in human populations.   
To begin to better understand the genetic mechanisms of aging within population-based 
studies of human, we first focus on defining a measure of aging among five cohorts 
representing over 30,000 individuals of ages ranging from 14 to 90 years of age who have not 
been selected on the basis of any health measures or outcomes. Next, to determine if there is a 
significant genetic component to this measure of aging, the heritability was also estimated in 
three different pedigree structures: large pedigrees (up to five generations), small pedigrees 





 Aging traits were first developed based on individuals aged 20-89 years of age and of 
European-descent from five genetic cohorts. The sample included 9,612 individuals from the 
Atherosclerotic Risk in Communities Study (ARIC), 3,018 individuals from the offspring cohort of 
the Framingham Heart Study (FHS), 6,135 individuals from the SardiNIA Study on Aging 




TwinsUK Study (TwinsUK), totally 33,601 individuals.   Heritability was assessed among the four 
cohorts ascertained as relatives (FHS, SardiNIA, TG, and TwinsUK), which included 23,989 
individuals. 
 The ARIC study is a prospective study designed to investigate the etiology of 
atherosclerosis (The ARIC Investigators, 1989) and included only individuals aged 44-65 years of 
age at baseline. While there were four recruitment sites (Forsyth County, North Carolina, 
Jackson, Mississippi, the suburbs of Minneapolis, Minnesota, and Washington County, 
Maryland) in the study with a total sample of 15,792 individuals, this investigation contains only 
the participants who were of European descent and had complete data for the variables of 
interest (n=9,633). Participants of African descent were not included, so the sample would be 
more homogeneous genetically to the other cohorts. Baseline data collection occurred between 
1986 and 1989. Because this cohort does not contain family information, their data was 
employed in creation of the aging traits, but not used in the heritability analyses.  
 Although the FHS was started in 1948 as a prospective investigation of coronary heart 
disease (Dawber, 1950) in Framingham, Massachusetts, this investigation included participants 
of the offspring cohort, who were the descendants of the initial cohort participants. Initial 
examinations for this cohort began in 1971 (Kannel, 1979), but only information from the 
seventh visit contained the variables of interest and was included. Visit seven occurred in the 
early 2000’s. Use of the offspring cohort also allowed us to study the heritability of the traits in 
small pedigrees. This sample contained a total of 1,749 families, with over two-thirds of the 




years-old and have completed an informed consent were eligible for participation. Individuals 
were excluded from the study if they had an allergy to latex; had active Reynaud's disease, as 
manifested by daily attacks of Reynaud's currently blue fingers or ischemic finger ulcers; had in 
the past had a radical mastectomy on right side; or who refused or withdrew from the test. 
 The SardiNIA Study is a prospective study containing close to 60% of the inhabitants of 
four regions in southeast Sardinia, Italy. Baseline visits began in late 2001 (Pilia, 2006) and the 
study is currently conducting the fourth visits. This investigation used information from the first 
three visits, which were conducted approximately 3-years apart. This cohort contains a rich 
selection of physiologic measurements on all participants and includes 588 large multi-
generation pedigrees. The number of generations represented ranged from one to five, with an 
average of three generations. 
 Both of the twin studies included in this investigation are European (TwinGene in 
Sweden and TwinsUK in the United Kingdom) and contain a combination of monozygotic and 
dizygotic twins. Each study contains approximately two-thirds dizygotic twins and one-third 
monozygotic twins. All pedigrees contained only the twins and therefore included only one 
generation of individuals. The studies differed in their recruitment of participants and age-
distributions. 
The TG project contains approximately 10,000 participants drawn from the Swedish 
Twin Registry (Katsika, et.al, 2010). The Swedish Registry was established in the 1960s to study 
how smoking affects our health and at present contains information on approximately 85,000 




1958 and contained individuals who completed self-reported questionnaires on health and 
medication data are collected from self-reported questionnaires. Blood sampling materials 
were then collected at a local health care center and a health check-up was administered. In 
the simple health check-up, height, weight, circumference of waist and hip, and blood pressure 
were measured (http://ki.se/ki/jsp/polopoly.jsp?l=en&d=13903&a=30244).  
The TwinsUK study contains approximately 12,000 twin volunteers from the UK Adult 
Twin Registry, which was started in 1992 (Moayyeri, 2012).  Blood draws for collection of DNA 
for use in genetic studies occurred between April 2004 and May 2007 and were collected on a 
total of 5,024 individuals who were active and consented for genetic studies. Although the age 
range of the full cohort spanned 18 to 108 years, individuals participating in the genetic portion 
of the study tended to be younger, with an age range of 18 to 80 years. 
 
2.2.2 Predicted Age Differential 
 To quantify the variation in aging between individuals, we first estimated a “biological” 
age based on physiological traits for each individual. Physiologic trait selection was done 
originally using the SardiNIA sample and began with forty quantitative traits known or 
hypothesized to be associated with aging and which has very low rates of missing values (< 
0.5%). Traits examined included: four anthropomorphic traits (waist circumference, height, 
weight, and BMI), immunologic measures (basophils, eosinophils, monocytes, lymphocytes, 
neutrophils, white blood cell count, IL-6, and C-reactive protein), lipid measures (total 
cholesterol, HDL, LDL, and triglycerides), liver measures (AST, ALT, bilirubin, and gamma GT), 




transferrin, and mean corpuscular volume), adipokines and glycoproteins (adiponectin, leptin, 
and fibrogen), glucose metabolism (insulin, glucose, and HbA1c), atherosclerosis measures 
(intima medial thickness, SBP, and DBP), and serum measures of uric acid, sodium, potassium, 
and creatinine (or estimated glomerular filtration rate, using the CKD-Epi formula). A detailed 
description of the measurements of all traits has been previously described in the 2006 paper 
by Pilia, et.al.  
Using linear regression with forward selection and assessing the partial R2 of each trait, 
it was found that the majority of the variation in age could be explained by three traits that 
were common between all of the cohorts involved in the study, which included: serum 
creatinine, waist circumference, and systolic blood pressure. After inclusion of these three traits 
in the model, additional traits explained less than 1% of the remaining variability. A full-list of 
the traits investigated along with their univariate estimates can be found in Table S2.1. To 
account for the use of anti-hypertensive medication use, the standard adjustment used in 
genetic studies of adding 10 mmHg to the reported SBP for all individuals taking anti-
hypertensive medications was implemented. 
 The first trait estimated, predicted age differential, is the difference between this 
estimated “biological” age for each person and their real age (i.e., the residual from the 
predicted age model). More specifically, predicted age differential = Agei – Predicted Agei, 
where Predicted Agei =  ̂   ∑  ̂    
 
    . The trait yields a positive number if the individual is 
older biologically or a negative number if the individual is younger biologically than their actual 




Examination of the predicted ages vs. age revealed a floor/ceiling effect or regression to the 
mean effect, where very young individuals were much more likely to be predicted older than 
they were and very old individuals were predicted to be younger than they were. Efforts were 
made to improve the fit, by employing the use of squared and cubic terms, but the extra terms 
did not improve the fit (Figure S2.1). This was expected, as closer investigation within the 
SardiNIA study showed a fairly linear association between age and the three physiologic 
measurements used to predict it (Figure S2.2). To correct for this bias, the differences between 
predicted age and actual age were calculated for each individual were standardized within age 
decade, as a post-hoc adjustment. 
 To validate the predicted age differential was actually indicative of health; associations 
were examined between the standardized trait and death, as well as, the prevalence of 
comorbid conditions within the SardiNIA cohort, using logistic regression. These models 
accounted for family clustering using a generalized estimating equation, with compound 
symmetry covariance structure. Conditions examined included: gastro-intestinal, blood 
disorders, bone, cancer, cardiac, cerebrovascular, depression, diabetes, endocrine, 
hypertension, immunological, kidney/urinary, dyslipidemia, liver, lung, metabolic, neurologic, 
and skin.  
In the final models, predicted ages were obtained separately by each cohort, using 
linear mixed models, which accounted for family clustering. As a sensitivity analysis, using the 




random effect. The two models did not differ meaningfully and therefore the simpler and more 
expedient approach was used for all cohorts. Models were adjusted for sex. 
  
2.2.3 Mortality Risk Differential 
 A second aging trait was also explored that incorporated an individual’s risk of death 
based on the same three physiologic traits used in the predicted age modeling. This method 
employed the use of census mortality rates or counts per population (specific to each of the 
cohort populations in the study). Each person’s estimated 1-year survival predicted by the three 
physiologic traits was compared to the national statistics and individuals were assigned a “risk” 
age that was equal to the census age at which the mortality risks were equivalent. The 
difference between this risk age and actual age was then computed. An example person is 
displayed in Supplementary Figure S2.3. 
US mortality rates were determined from the Social Security Administration actuarial 
life tables (http://www.ssa.gov/oact/STATS/table4c6.html), Sardinian mortality estimates were 
calculated from Italian government website (http://demo.istat.it/unitav/index.html#), Swedish 
estimates were taken from Eurostat European Commission data base 
(http://epp.eurostat.ec.europa.eu/portal/page/portal/population/data/database), and UK 
mortality was estimated from the UK Office for National Statistics 
(http://www.ons.gov.uk/ons/taxonomy/index.html?nscl=Mortality+Rates).  
 Because survival curves and predicted risk of 1-year mortality are expected to be very 




1-year survival for each individual based on their covariate values and the estimated baseline 
hazard for all cohorts where specific entry time and censoring data was available (ARIC, FHS, 
TG, and TwinsUK). In the SardiNIA study, where age of death was known for individuals who 
died during follow-up, a discrete survival analysis was employed using a repeated-measures 
logistic model, which employed the information available from the three visits for each 
individual. This model was used to estimate the 3-year odds of survival for each individual. 
Mortality analyses were run separately for males and females, since some sex-specific 
differences were observed in the association between physiologic traits and mortality risk. For 
display in the graphics, the risk age was centered for each cohort. This has no effect on the 
estimation of heritability or interpretation of results because it is simply a scalar shift.  
 To allow for comparison between the SardiNIA mortality results and the other cohorts 
by using a Cox regression, two assumptions were made to create the follow-up time 
information needed. First, individuals who did not die during the study follow-up were 
censored at their last visit. Secondly, for individuals who died during the study, their date of 
death was assumed to be during the middle of the year of their reported age of death. 
 All analyses excluded individuals greater than 90 years of age, since the association 
between physiologic measures and age often differs in this age group, compared to younger 






2.2.4 Heritability Analysis 
 Narrow-sense heritability was estimated for each trait by cohort, based solely on their 
phenotypes, using variance-component based estimation. This was accomplished by fitting a 
simple model with two variance components (a heritable additive polygenic component and an 
individual specific environmental component) and two covariates (sex and age). Estimates were 
calculated for the full-sample within each cohort and also for a restricted sample of individuals 
aged 45-65. This age range was common across the five cohorts and within the range of data 
where model fit was best. This age range also contains ages at which humans begin to see age-




 Differences were observed in the age distributions between the different cohorts, as 
displayed in Figure 2.1. The SardiNIA study had the widest age range (14-90 years), while the 
ARIC study had the smallest age range (44-66 years). FHS and TwinGene studies lacked young 
individuals and contained individual’s whose ages ranged from the mid-forties to 90. The 
TwinsUK study was the youngest cohort included with ages ranging from 18 to 80, but 
contained very few individuals over 70 years of age. 
 The characteristics of interest for this study are shown in Table 2.1 for each cohort. As 
illustrated by the distributions displayed in figure 2.1, the SardiNIA and TwinsUK studies had the 




low to mid-sixties. All cohorts were > 50% female, but the TwinsUK was overwhelmingly female 
with only 8.6% males. Serum creatinine values were highest in the ARIC and FHS studies, with 
means greater than 1 mg/dl. In all cohorts males had higher creatinine values than females. 
Average SBP ranged from 120 to 140 mmHg between the cohorts, with the highest means 
observed in the oldest cohorts. Waist circumference was also highest in the oldest cohorts and 
larger among the male participants. The percentage of individuals receiving an anti-
hypertensive medication differed markedly, with a higher prevalence of use in the oldest 
cohorts. 
  Tables 2.2 and 2.3 contain the model fit estimates by cohort. As expected, mainly 
significant and positive associations were seen between each physiologic measure and age 
(Table 2.2), although variation is seen between the cohorts. The magnitude of the regression 
coefficient was largest for the SardiNIA study, which had the largest range of ages, while the 
smallest effect sizes were seen in the ARIC cohort which had the tightest age range.  
 Estimates from the Cox mortality models showed more variation between the cohorts 
(Table 2.3), although almost all were in the expected direction of higher values being associated 
with a higher hazard ratio. The mortality HR for creatinine and waist circumference was largest 
in the older cohorts among males (SardiNIA: HR=1.06 for 0.1 higher creatinine and HR=1.16 for 
5 cm larger waist circumference; TwinGene: HR=1.08 for 0.1 higher creatinine and HR=1.09 for 
5 cm larger waist circumference).  
 Very similar estimates were seen for the odds of death using the discrete survival model 




0.1 higher creatinine (p=0.0005) and a 9% increase in the risk of death for every 5 cm larger 
waist circumference (p=0.005). Systolic blood pressure was not highly predictive of mortality, 
although border-line significant (p=0.05), and was in the opposite direction as expected. The C-
statistic for concordance was quite high at 0.86. 
 Table 2.4 contains the odds ratios for the association between the predicted age 
difference trait and the odds of mortality, as well as prevalence of other comorbid conditions, 
among the SardiNIA sample. The trait was significantly associated with death (OR=1.60, 
p=0.0002). It was also significantly associated with the comorbid conditions typically defined by 
the three physiologic traits used to create the trait: metabolic syndrome (OR=1.55 per 1 SD 
higher, p<0.0001), hypertension (OR=1.48 per 1 SD higher, p<0.0001), and kidney/urological 
disease (OR=1.41 per 1 SD higher, p<0.0001). It was also found to be associated with other 
comorbid measures such as immunologic disease (OR=1.27 per 1 SD higher, p=0.03), diabetes 
(OR=1.24 per 1 SD higher, p<0.0001), coronary artery disease (OR=1.20 per 1 SD higher, 
p<0.0001), and depression (OR=1.11 per 1 SD higher, p=0.03).  
 Figure 2.2a displays the floor/ceiling effect seen in the predicted age estimates from the 
linear models before standardization, for each cohort. The floor/ceiling effect is more 
pronounced for cohorts with a smaller age range, where as the model fits much better in the 
SardiNIA cohort with the large age-range, except in the very young and very old individuals. 
Figure 2.2b shows the risk age estimates plotted by age. Although the estimates don’t appear 
to be linear along the full range of ages, less deviation between the expected and observed 




 Histograms of the two traits are displayed in Figure 2.3. The predicted age differential is 
normally distributed, as expected, because it was standardized within age decade. The 
distribution of the mortality risk differential nears normal, but it slightly bi-modal, with a small 
second node to the left. This reflects that fact that separate mortality models were estimate per 
sex and compared to sex-specific census values in each cohort. Heritability analyses were 
adjusted for sex to assure this did not affect the estimates. 
 
2.3.2 Heritability 
 Heritability estimates for the four related cohorts are shown in Figure 2.4. Estimates 
vary markedly when comparing the twin studies with the cohorts that include parental 
phenotypes. Estimates for the heritability of the predicted age differences differ less markedly 
and range from 0.25-0.33 in the non-twin studies compared to 0.70 in the twin studies. 
Estimates of h2 for the twin studies for the risk age trait are questionably high and reasons for 
this will be discussed, while estimates for the SardiNIA and FHS studies, using the Cox model 
were markedly low. The heritability estimated within the SardiNIA study using the discrete 
survival model, which estimated a 3-year showed higher heritability (h2=0.30) than the 1-year 
survival estimates from the Cox model.  
 When heritability estimation was restricted to the sample of 45-65 year old individuals 
in each cohort, the heritability estimates were much more similar (h2=0.30 in FHS, h2=0.54 in 




Estimates were more variable for the risk age differences, likely due to the difference age-
ranges in which the models estimates were devised. 
  
2.4 Discussion 
  Two different measures of aging were developed in this study among five cohorts with 
varying ranges of ages and pedigree structures. The measure based on predicted age showed 
more consistent heritability estimates across the different cohorts ranging from 25% in the full 
SardiNIA sample to 70% in the TwinsUK study. The trait based on an individual’s risk of 
mortality was less consistent across the studies and within the SardiNIA cohort varied 
depending on the type of mortality model used to estimate 1-year and 3-year survival. 
Estimates within the twin studies were quite high and possibly not valid, due to the lack of 
substantial differences seen in the predicted 1-year survival between twin pairs, even when the 
co-twins had differing physiologic traits. 
Both aging traits are highly dependent on obtaining good predictions of both age and 
mortality risk. Having a larger range of ages in a cohort yielded the best model fit for predicting 
age. The three physiologic traits chosen for this analysis were based on work in the SardiNIA 
study, which had the largest age range. These same three measures were then examined in the 
other cohorts, so that heritability estimates would be comparable and future genome-wide 
association studies could be conducted. Without that aim in mind, it is highly likely that 
different physiologic measures may have been better at predicting age in the other cohorts and 




The cox proportional hazards models depend highly on having a sufficient number of 
individuals of advanced age and deaths for good fit. All three of the physiologic traits (serum 
creatinine, SBP, and waist circumference) showed a positive association with age, but the 
association was stronger in cohorts with more individuals of older ages. Therefore cohorts, such 
as the TwinsUK cohort whose average age is only 47.5 years and contains very few individuals 
over the age of 70 years, showed weaker associations between the physiologic traits and 
mortality. The ARIC study, which had the smallest age range, also did not show large 
associations between the measures and mortality, nor did the SardiNIA study, which has the 
highest percentage of very young individuals. 
 Having a way to measure aging among individuals of varying ages could be very useful in 
furthering our understanding of the genetics of aging. Most work in this field has been limited 
to studies of longevity, focusing on individuals who have attained a specific age. These studies 
have shown heritability estimates between 20-30% (Sebastiani and Perls, 2012), even among 
twins. Other studies among humans have focused on the mitochondrial DNA (De Benedictis, 
1999) haplogroups of centenarians and found variants associated with longevity. Animal studies 
have had more success than studies among humans in detecting variants with large effects on 
longevity (Paaby and Schmidt, 2009), and while these studies have informed human studies, 
they aren’t often directly applicable.  
While estimates of predicted age were fairly consistent across the cohorts in our study, 
there may be an alternate explanation of the estimates of heritability for the risk age trait in the 
twin studies. Estimates of survival are highly dependent on age. Because the twin pairs are the 




pairs, this led to both twins being assigned the same risk age and in-turn the same risk age 
difference. With near perfect correlation within twin pairs, the h2 estimates will be biased 
upward.    
 Although the results of this work may not be directly clinically applicable, there are 
genetic components of aging that can be discerned with this technique. Future work focused on 
discovering the loci and pathways involved may facilitate the ability to detect an individual’s 
risk for accelerated aging. Individual’s at high risk for accelerated aging could be followed more 
closely by their physicians and could potentially lower their risk by avoiding high risk and 
unhealthy behaviors. 
There are some limitations in this study. In particular to allow for comparability between 
the different cohorts, the same three physiologic measures were used to predict age and the 
risk of mortality. These measures were selected from SardiNIA may not be the most 
appropriate for other studies because of differences in individual characteristics and age. 
Improvements are expected if cohorts developed their own list of physiologic traits to be used 
in the predictive equations. We also would not expect all predictors of age to be linear across 
the entire age range, although they were fit this way in the current analysis. Squared and 
quadratic terms were tested and did not show an improvement in fit. Had data been available 
on hormone levels or menopause status, this would have been an important factor to examine 
in relation to the shape of the physiologic and age associations. 
Also, the use of 1-year survival estimates vs. a longer follow-up may have limited the 




model could improve this limitation, as evidenced from the discrete survival model employed in 
the SardiNIA sample. Heritability estimates were greatly increased by the use of 3-year 
probability of dying vs. the 1-year survival estimate from the Cox model. 
This study indicates that investigations in the genetics of aging do not need to be limited 
to special cohorts of very advanced ages. By defining an individual’s biological age we can 
investigate the difference between their actual age and the age of their body. Variation does 
exist in this difference that is heritable and future work will attempt to link this variability to 
specific genetic loci. 
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Figure 2.1: Comparison of Age Distributions, by Cohort. A: ARIC, n=9,633. B: FHS, n=3,232. C: 













Table 2.1: Characteristics Used in Estimating Measures of Aging, by Cohort.  
Measure 













      
Demographics: 
   Age (years)       
      All 54.3 (5.7) 61.3 (9.7) 49.6 (17.6) 64.8 (8.5) 47.5 (13.0) <0.0001 
      Males 54.7 (5.7) 61.3 (9.7) 49.7 (18.0) 65.5 (8.0) 46.5 (13.4) <0.0001 
      Females 54.0 (5.7)  61.4 (9.7) 49.6 (17.4) 64.3 (8.1) 47.6 (13.0) <0.0001 
   Male (%) 47.0 46.1 42.5 47.5 6.9 <0.0001 
      
Physiologic Traits: 
   Creatinine (mg/dl)       
      All 1.09 (0.18) 1.07 (0.32) 0.76 (0.22) 0.88 (0.32) 0.76 (0.18) <0.0001 
      Males 1.20 (0.16) 1.19 (0.35) 0.86 (0.24) 0.99 (0.40) 0.92 (0.17) <0.0001 
      Females  0.98 (0.14) 0.97 (0.24) 0.68 (0.18) 0.79 (0.16) 0.75 (0.17) <0.0001 
   SBP (mmHg)*       
      All 120.4 (18.5) 130.6 (20.9) 127.1 (20.2) 141.3 (20.4) 120.8 (17.6) <0.0001 
      Males 122.1 (17.5) 131.8 (19.4) 131.9 (18.9) 142.5 (20.0) 120.3 (17.7) <0.0001 
      Females 118.9 (19.2) 129.6 (22.0) 123.6 (20.5) 140.3 (20.7) 127.8 (15.1) <0.0001 
   Waist circ. (cm)       
      All 96.2 (13.3) 99.8 (14.1) 84.8 (13.1) 91.7 (12.3) 80.8 (11.3) <0.0001 
      Males 99.6 (10.4) 103.3 (11.2) 90.2 (11.3) 97.1 (10.5) 94.1 (10.1) <0.0001 
      Females 93.1 (14.8) 96.8 (15.5) 80.8 (13.0) 86.8 (11.7) 79.8 (10.7) <0.0001 
       
Treatment: 
   Antihypertensive  
   medication (%) 
      
      All 19.7 34.4 13.8 23.9 8.0 <0.0001 
      Males 20.1 37.5 14.5 24.8 0.0 <0.0001 
      Females 19.4 31.8 13.4 23.1 8.6 <0.0001 




Table 2.2: Linear Mixed Model Estimates by Cohort for Predicted Age.*  
Cohort N R2** 
Serum Creatinine  
(per 0.1 mg/dl) 
SBP  
(per 10 mm/Hg) 
Waist  
(per 5 cm) 
β p β p Β p 
         
ARIC 9,612 0.09 0.30 <0.0001 0.9 <0.0001 0.02 0.34 
FHS 3,018 0.18 0.53 <0.0001 1.8 <0.0001 -0.02 0.75 
SardiNIA 6,135 0.47 0.69 <0.0001 3.6 <0.0001 2.71 <0.0001 
TwinGene 9,999 0.13 0.34 <0.0001 1.3 <0.0001 -0.10 0.002 
TwinsUK 4,838 0.19 0.69 <0.0001 2.4 <0.0001 1.12 <0.0001 
         
*Adjusted for sex 




Table 2.3: Hazard Ratios for Time to Death Models* for all Cohorts and Odds Ratio for Discrete 
Survival in SardiNIA. 
Cohort N Deaths 
Serum 
Creatinine 
(per 0.1 mg/dl) 
SBP 
(per 10 mm/Hg) 
Waist 
(per 5 cm) 
HR p HR p HR p 
       
ARIC         
   Females 5,089 572 1.03 0.34 1.10 <0.0001 1.03 0.048 
   Males 4,521 860 1.01 0.66 1.05 0.02 1.08 <0.0001 
         
FHS         
   Females 1,606 123 0.96 0.33 1.07 0.11 1.01 0.75 
   Males 1,410 202 1.07 <0.0001 1.08 0.046 1.11 0.0014 
         
SardiNIA         
   Females 3,392 101 1.03 0.40 0.94 0.18 1.02 0.51 
   Males 2,505 133 1.06 0.10 1.04 0.36 1.16 0.005 
         
TwinGene         
   Females 5,265 191 1.08 <0.0001 0.97 0.30 1.09 0.003 
   Males 4,734 304 1.03 <0.0001 0.99 0.73 1.03 0.35 
         
TwinsUK         
   Females 4,505 235 1.02 0.35 1.04 0.19 1.01 0.71 
   Males 333 17 1.16 0.25 1.18 0.25 1.33 0.035 
         
         
Discrete Survival Model 





(per 0.1 mg/dl) 
SBP  
(per 10 mm/Hg) 
Waist 
(per 5 cm) 
OR p OR p OR p 
SardiNIA 0.86 1.06 0.0005 0.94 0.05 1.09 0.005 
         






Figure 2.2: Comparison of age traits to age, by cohort 
  
  
A. Predicted age by age, before standardization 




Figure 2.3: Histogram of the Distribution in Predicated Age Differential and Risk Age Differential 
A. Predicted Age Differential (Standardized within Age Decade) 
 
 






Table 2.4: Odds Ratios of Death or New Disease in SardiNIA Sample by Predicted Age 
Measure 





   
Death 1.60 0.0002 
Metabolic Disorder 1.55 6.2e-9 
Hypertension 1.48 <1e-30 
Kidney or Urologic Disease 1.41 <1e-30 
Immunological Disorder 1.27 0.03 
Diabetes 1.24 1.4e-7 
Coronary Heart Disease 1.20 3.1e-6 
Cerebrovascular Disease 1.17 0.21 
Depression 1.11 0.03 
Gastro-intestinal Disorder 1.07 0.12 
Skin Disease 1.05 0.33 
Dyslipidemia 1.04 0.30 
Lung Disease 1.04 0.49 
Liver Disease 1.02 0.75 
Endocrine Disorder 1.00 0.96 
Bone Disorder 0.99 0.91 
Cancer 0.98 0.81 
Neurologic Disorder 0.94 0.38 
Blood Disorder 0.93 0.10 





Figure 2.4: Heritability Estimates by Trait and Cohort 
A. Full Age Ranges for Each Cohort 
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Table S2.1: Univariate Models for Choosing Traits for Predicted Age Model, SardiNIA Study, 
N=6,114. 
Measure Beta P-value Measure Beta P-value 
S. Creatinine (per 0.1 mg/dl)      1.0    <1e-30 MCV (per 1 fL)       0.3 <1e-30 
eGFR (per 10 ml/min)         -6.3     <1e-30 CRP (per 1 mg/dl)              1.5 6.3e-13 
SBP (per 10 mm/Hg)             5.2     <1e-30 Platelets (per 10^3/ul) -0.04 <1e-30 
DBP (per 5 mm/Hg)             3.9     <1e-30 Basophils (per 1 %) 0.5 0.3520 
Waist (per 5 cm)             3.7     <1e-30 Eosinophils (per 1 %)     0.6 2.7e-7 
Weight (per 5 Kg)            1.8     <1e-30 Lymphocytes (per 1 %)    -0.3 <1e-30 
Height (per 1 cm)           -0.71     <1e-30 Monocytes (per 1 %)       0.3 0.0022 
Ln IMT (per 0.1)             6.4    <1e-30 Neutrophils (per 1 %)        0.2 1.9e-11 
BMI (per 1)               1.95     <1e-30 Potassium (per 1 mEq/L) 8.8 <1e-30 
Bilirubin (per 0.1 mg/dl)      1.5    4.2e-7 RBC (per 10^6/uL)       -1.9 2.6e-6 
ALT (per 5 U/L)             0.4   2.3e-14 Iron (per 5 microU/L 0.1 0.0016 
AST (per 5 U/L)              0.9     <1e-30 Sodium (per 1 mEq/L)      0.6 <1e-30 
Uric Acid (per 1 mg/dl) 3.4     <1e-30 Transferrin (per 10 mg/dl) -0.4 <1e-30 
Total Chol (per 10 mg/dl       1.7    <1e-30 Triglyc. (per 10 mg/dl 0.5 <1e-30 
GammaGT (per 10 U/L)         0.8   <1e-30 Fibrinogen (per 10 mg/dl)     0.7 <1e-30 
Glucose (per 10 mg/dl) 2.4     <1e-30 WBC (per 10^3/ul)      -0.9 6.5e-11 
HDL (per 5 mg/dl)     1.4   <1e-30 IL6 (per ug/mL)       1.0 <1e-30 
HbA1C (per 0.5)           3.8     <1e-30 Leptin (per 100 pg/mL)   0.03 <1e-30 
Insulin (per 5 mU/L) 0.8     1.4e-8 Adiponectin (per mg/mL) 0.9 <1e-30 






Figure S2.1: Comparison of Residual Plots for Predicted Age using Linear and Squared 
Physiologic Traits as Predictors 
A. Linear Predictors of Age (S. Creatinine, SBP, Waist): 
 









Figure S2.2: Distribution of Three Physiologic Measurements used to Predict Age and Mortality 
Risk over Age Quartile Range from the SardiNIA Study 
A. Creatinine (mg/dl) 
 
 
B. Waist Circumference (cm)  
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Figure S2.3: Example of Risk Age Trait for an Individual Aged 82, with S. Creatinine of 0.95 
















0 0.1 0.2 0.3 0.4 0.5 0.6 0.7
Female 
Age = 82 
S. Creatinine = 0.95 
SBP = 135 
Waist = 67 
P(death in 3 years) = 0.057  
Risk age = 74 
Age Difference = - 8 years 
Risk Age 










 While genome-wide significant studies (GWAS) have uncovered a host of loci associated 
with age-related diseases (Jeck, et.al, 2012), to date, no genome-wide association consortia of 
aging have detected any single nucleotide polymorphisms (SNPs) significant at p < 5 x 10-8. A 
large meta-analysis of genome-wide association studies from nine studies from the Cohorts for 
Heart and Aging Research in Genomic Epidemiology Consortium was recently conducted for 
two outcomes: a) all-cause mortality and b) survival free of major disease or death and also 
failed to produce genome-wide significant findings (Walter, et.al, 2011).  
 As evidenced in the Walter et.al study, work in this area has typically focused on 
morality as the measure of aging. We propose a different approach that will be more applicable 
to general population studies with a wide range of ages. As described in detail in previous work 
(Chapter III), we have developed two different measures of aging that compare a person’s 




information from four family-based cohorts, both traits have moderate heritability with 
estimates ranging from 0.25 in a small pedigree setting to 0.70 among twins for the predicted 
age differential. 
 The current work focuses on these traits in five cohorts of varying pedigree structures to 
determine if genomic regions associated with measures of aging could be identified and 




 The same five cohorts that were described in Chapter II were used in this analysis. All 
five cohorts are longitudinal cohort studies and included the participants of European-descent. 
A total included: 9,612 individuals from the Atherosclerotic Risk in Communities Study (ARIC, 
The ARIC Investigators, 1989), 3,018 individuals from the offspring cohort of the Framingham 
Heart Study (FHS, Dawber, 1950 and Kannel, 1979), 6,135 individuals from the SardiNIA Study 
on Aging (SardiNIA, Pilia, et.al, 2006), 9,998 twins from the Swedish TwinGene Study (TG, 
Katsika, et.al, 2010), and 4,838 twins from the TwinsUK Study (TwinsUK, Moayyeri, 2012), 
totally 33,601 individuals.  ARIC, FHS, SardiNIA, and TwinsUK (approximately 20,000 individuals 
with genotype data) were used in the discovery stage of this analysis and TwinsUK will be used 






 Two traits were developed (predicted age differential and mortality risk differential) to 
measure aging among population samples of individuals of varying ages. A full description can 
be found in Chapter II of this dissertation, but briefly, the traits are both based on the 
difference between an individual’s estimated “biologic” age and their actual age. Both traits 
employed three common physiologic measures to estimate biologic age: serum creatinine, 
systolic blood pressure, and waist circumference. An increase in the value of each trait was 
generally associated with an increase in estimated biologic age. 
 The first trait employed mixed linear regression, accounting for family clustering, to 
predict and individual’s biologic age. The second trait was based on the individual’s risk of 
mortality, (1) using Cox proportional hazards models for all cohorts for 1-year and (2) Cox 
models for all cohorts, except for SardiNIA, for 3-year survival estimates. The SardiNIA study 
employed discrete survival analysis, using repeated measures logistic regression compared to 
the mortality risk of the appropriate country’s census data. Each individual was then assigned a 
“risk” age that was equal to the age at which the individual’s survival estimate was equivalent 
to the census survival estimate. Both traits are the difference between the estimated biologic 
age and actual age. For example, predicted age differential = Agei – Predicted Agei, where 
Predicted Agei =  ̂   ∑  ̂    
 
    . Both traits yield a positive number if the individual is older 
biologically or a negative number if the individual is younger biologically than their actual 






3.2.3 Genotype Data and Imputation 
 Genotype data came from a variety of chip platforms, but were all imputed on the 
HapMap2 reference panel, release 22, build 36, CEU population 
(http://hapmap.ncbi.nlm.nih.gov/, The International HapMap Consortium, 2007).  Data was 
downloaded from dbGaP (http://www.ncbi.nlm.nih.gov/gap ) for the ARIC and FHS cohorts, 
while data was contributed through collaboration with the TwinGene and TwinsUK cohorts.  
 The FHS cohort employed a combination of Affymetrix 500K and MIPS 50K chip (for a 
total of 534,982 genotyped SNPs) and used MACH (version 1.0.15, Li, et.al, 2010 and Li, et.al, 
2009) to impute autosomal SNPs.  
 Genotype data for the ARIC study came from the Affy 6.0 chip, while the SardiNIA 
cohort used a combination of the Affy 50K, 500K, and 6.0 chips. The ARIC and SardiNIA cohort 
data was imputed, in-house. As all ARIC samples were genotyped on the same chip a single 
imputation was run using a combination of MACH for phasing and Minimac software (Kim, 
http://genome.sph.umich.edu/wiki/Minimac) for imputation. 
As the SardiNIA cohort contained individuals genotyped on three different chips, a two-
step imputation was run: one haplotype-based and one family-based (Naitza, 2012). The first 
was based on imputing separately samples typed with the 500K (N=1412) and with the 6.0 
array (N=1097), treating individuals as unrelated. The best guessed genotype (not the dosages) 
were chosen for all SNP with RSQR >0.3. Using the best guessed genotypes from the two 




discarded if there were an excess of Mendelian errors. Finally, the individuals typed with the 
10K array were merged back into the data and family-based imputation was implemented using 
Merlin, which imputes SNPs based on the estimated haplotype transmission. This imputation 
was possible because samples typed with 500K and 6.0 were mostly founders and key 
descendents, so one needed to follow the haplotype inheritance flow estimated using markers 
in common between the 10K chip and the 500K/6.0 arrays to accurately impute SNPs (Burdick, 
et.al, 2006). 
 For the TwinsUK sample, 5710 twins have undergone a genome-wide scan of either 
317,000 SNP markers (Illumina HumanHap300 Bead Chip) or 610 000 SNPs (Illumina 
HumanHap610 Quad Chip). The data have been fully imputed using IMPUTE version 2 software 
(Howie BN, et.al., 2009) and quality checked (Moayyeri, 2012). 
 A summary table of genotyping and imputation procedures can be found in 
Supplementary table S3.1. 
 
3.2.4 Statistical Analysis 
 Genome-wide association models were run using Merlin software (Abecasis, 2002) for 
the ARIC, FHS, and SardiNIA Studies and Genabel (Aulchenko, 2007) for the TwinsUK Cohort 
using an additive model and fitted dosage data for each SNP. The reported pedigree structure 
was used in the form of the kinship matrix to account for relatedness in the three family-based 
studies. Each trait was examined unadjusted, adjusted for age, and adjusted for age and sex. It 




trait, to account for the standardization of the trait within age decade. On average 2.5M SNPs 
were available for analysis in each cohort. All SNPs with minor allele frequency (MAF) greater 
than zero were examined.  
Quantile-quantile (QQ) plots and genomic control (GC) values were calculated using R 
software (R Development Core Team, 2008), to assess population substructure. GC values 
ranged from 0.98 to 1.09 for the predicated age trait (Figure 3.1 displays plot for each cohort 
adjusted for age) and 0.92 to 1.09 for the risk age trait (Figure 3.2 displays plot for each cohort 
adjusted for age). Although the GC values and QQ plot for FHS appear to show an 
overcorrection for pedigree structure in the age risk trait, no problems could be detected from 
the pedigree data downloaded from dbGaP. All SNPs with imputation quality < 0.30 were 
removed before analysis and therefore not the cause. 
Meta-analysis was performed, using METAL software (Willer, 2010), to combine the 
evidence for association from the four individual studies. Two weighting schemes, sample size 
and standard error, were investigated and showed similar results. Heterogeneity between the 
studies was also assessed. SAS (SAS, Cary, NC) was employed for creation of all traits and Locus 
Zoom (Pruim and Welch, 2010) was used to create plots of interesting genomic regions. 
 
3.2.5 Bioinformatic analysis of functional implications of genetic variants 
 Variants with p < 5 x 10-6 were analyzed by computational methods to infer potential 
functional relevance. Conservation analysis was performed using the comparative genomics 




nine eutherian mammals, including chimp, mouse and pig. To analyze the putative biological 
effects of each exonic or intronic variation, either the major or minor allele was input into 
predictive programs flanked on either side by 100 bp of sequence. Potential human 
transcription factor binding sites were analyzed using default parameters of the transcription 
element search system from the University of Pennsylvania (http://www.cbil.upenn.edu/cgi-
bin/tess/tess).  SNPs were interrogated for effects on expression levels, i.e. whether they are 
expression quantitative trait loci (eQTLs) for that gene using the SNP and CNV Annotation 
(SCAN) Database (http://www.scandb.org/newinterface/about.html) from the University of 
Chicago.  This database includes information on expression levels in numerous populations, 




 One SNP (rs10496861) reached genome-wide significance in this study for the trait 
based on the difference between predicted age and age, after adjustment for age (table 3.1). 
The SNP is located within an intronic region of the gene LRP1B  which produces low density 
lipoprotein receptor-related protein 1B. The direction of association was the same within all 
four cohorts and there was no significant heterogeneity found. Minor allele frequency (MAF) 
for this SNP is 34%. The meta-effect size is +0.28 with a p = 5.75 x 10-9. Because the trait was 
standardized by age decade this effect size translates into varying age differences, based on an 
individual’s age. Standard deviations by age decade ranged from 7 to 11 years in all cohorts, so 




age difference for each age range. The Locus Zoom plot of this SNP (Figure 3.3) shows the 
typical spike compared to the surrounding regions. 
 Table 3.1 also displays the SNPs that were found to be marginally significant (5 x 10-8 < p 
< 5 x 10-7) and SNPs of interest for validation (5 x 10-7 < p < 5 x 10-6). Of particular interest is a 
set of SNPs on Chromosome 21 located between 20.7 and 20.8 Mb (Figure 3.4). These SNPs are 
approximately 500 Kb upstream of the NCAM2 gene. Seven SNPs in this region had a meta-
analysis p-values of 5 x 10-8 < p < 5 x 10-7 and 20 more SNPs in the region had meta-analysis p-
values 5 x 10-7 < p < 5 x 10-6. 
 Although one SNP (rs9472826 on Chromosome 6) also reached genome-wide statistical 
significance for the risk age trait, data was only available for analysis from the SardiNIA and 
TwinsUK cohorts and there was significant heterogeneity detected between the associations 
(Table 3.2).  The MAF for this SNP was less than 1% and therefore the finding is thought to be a 
false positive. Similar findings for a marginally significant SNPS (rs17476005) also on 
Chromosome 6, but in a different region, also point to it potentially being a false positive result. 
Two regions of modest interest were detected on Chromosome 18. The first region is very small 
and located around position 41.2 Mb (Figure 3.5), which is upstream of the SLC14A2 gene. 
Three SNPs were detected in this region with 5 x 10-7 < p < 5 x 10-6, with MAF of approximately 
2.5%. The second region is wider, spanning positions 53 to 53.1 Mb, and is upstream of two 
genes: ST8SIA3 and ONECUT2 (Figure 3.6). This region contained nine SNPs with significance 




 All SNPs with p < 5 x 10-6 are currently being follow-up in replication work planned 
among 10,000 individuals in the TwinGene cohort.  
 
3.3.2 Bioinformatic analysis of functional implications of genetic variants  
 The LRP1B gene is very large (1,900,279 bases) and belongs to the low density 
lipoprotein (LDL) receptor gene family (http://www.genecards.org/cgi-
bin/carddisp.pl?gene=LRP1B). These receptors play a wide variety of roles in normal cell 
function and development due to their interactions with multiple ligands (Liu et al., 2001) by 
producing cell surface proteins that bind and internalize ligands in the process of receptor-
mediated endocytosis. This gene has homologues in six other species: Mus musculus, Gallus 
gallus, Pan troglodytes, Canis lupus familiaris, Bos Taurus, and Danio rerio and has 41 known 
protein products (http://refgene.com/gene/53353). Using the University of California Santa 
Cruz genome browser (http://genome.ucsc.edu/cgi-
bin/hgTrackUi?hgsid=329521287&c=chr2&g=cons46way), a comparison of this SNP was made 
across 46 different vertebrate species (Figure S3.2).  Based on these findings is appears that this 
position/region is not highly conserved, nor highly divergent. 
Our top SNP rs10496861 is located in one of the 93 distinct introns [NM_018557.2] and 
has been shown to alter expression levels of the LOC407835, MAP2K2, and SLC38A5 genes 
within the Nigerian population (YRI) at a level p<0.0001, n=283. Expression work for the LRP1B 




a lesser amount in testis but absent in other tissues, including heart, kidney, liver, lung, and 
placenta (Haas, 2011).     
 
3.4 Discussion 
 Most human genetic studies of aging and longevity have focused on centenarians’ 
survival, or have been candidate gene studies focused on genomic regions suspected to be 
associated with aging. In a new approach, using two novel measures of aging developed in and 
applicable to adults of ages 20 to 90 years of age, this study was able to detect a genome-wide 
significant genetic association for aging. Each measure used an estimated biologic age for each 
individual and computed the difference between that age and the individual’s chronological 
age.  
 One SNP (rs10496861) on Chromosome 2 within the LRP1B gene reached genome-wide 
statistical significance with a p-value of 5.78 x 10-9 for the trait comparing predicted age to age 
in the meta-analysis. Because additive models were used, individuals with one additional copy 
of the minor allele (T compared to the wild-type G, with MAF=0.34) were on average +0.28 
standardized years older than individuals with the wild-type allele. Depending on the 
individual’s actual age, this translates into a 2 to 3 year above average biologic age compared to 
actual age, for each copy of the T allele. Another region of interest was found for this trait on 
chromosome 21 between position 20.7 and 20.8 Mb, with the most statistically significant SNP 
(rs1786357) just above genome-wide significance with a p-value of 7.64 x 10-8. Seven SNPs with 




 Although no SNPs reached genome-wide significance with the risk age trait, two regions 
of interest on Chromosome 18 showed promise (around position 41.2 Mb and between 53 to 
53.1 Mb). These regions are currently being followed-up in replication work in the TwinGene 
cohort. 
These findings are very exciting because if validated, may provide a way to detect an 
individual’s risk of accelerated aging before clinical symptoms can be detected for comorbid 
conditions such as hypertension, diabetes, and chronic kidney disease. Work from the CARDIA 
study (Lee DH, et.al, 2003) has found that early intervention at a young age can have effects 
long after.  With the current shift in the age distribution of the population, having a way to 
determine an individual’s risk for accelerated aging could be invaluable. We need to be able to 
single out high risk individuals and focus efforts to change behaviors and, if necessary, closely 
monitor them for early signs of diseases or comorbidities, such as high blood pressure or high 
glucose levels.  
There is support for the current LRP1B finding from previous work investigating 
successful aging (Poduslo, et.al, 2009). The study was very small (n=63) and included individuals 
aged greater than 85 years with Mini Mental State Examination (Folstein, 1983) scores > 26 and 
no major illness (cardiovascular problems, diabetes, obesity, major cancer diseases, or 
dementia in the family) were compared to a cohort of Alzheimer’s patients. They found that 
specific haplotypes (3 SNPs: rs12474609, rs10201482, and rs980286) in intron 18 of the LRP1B 
gene were significantly associated with successful aging after Bonferroni correction. These 




disequilibrium between them is very low, with r2 ranging from 0.02 to 0.033. Since their finding 
was based on Alzheimer’s patients and a large GWAS of Alzheimer’s patients was published in 
2011 (Hollingworth, et.al), their findings were examined for any hits in the LRP1B gene and non 
were found. 
LRP1B expression appears to be restricted to specific organ. mRNA was been detected in 
the human brain, thyroid gland, skeletal muscle, and testes (Haas, 2011). It is absent in other 
tissues, such as heart, kidney, liver, lung, and placenta. This could point to a speciation function 
of LRP1B in certain organs. Many of the LRP1B ligands are well known factors in blood 
coagulation and lipoprotein metabolism, which may suggest a possible role in atherosclerosis, 
which is directly correlated with aging. 
The biological implications described in the mRNA work above corroborate other studies 
that have linked this gene to phenotypes such as thyroid cancer, where inactivation of LRP1B 
results in changes to the tumor environment, conferring cancer cells an increased growth and 
invasive capacity (Prazeres, 2010) and insulin-resistance (Burgdorf, 2012). The rs2890652 locus 
upstream of LRP1B was associated with both increased BMI and decreased insulin sensitivity.  
Through bioinformatic investigation, our most significant SNP was shown to alter 
expression levels of the LOC407835, MAP2K2, and SLC38A5 genes MAP2K2 (mitogen-activated 
protein kinase kinase 2) is located on 19p13.3 and the protein encoded by this gene is a dual 
specificity protein kinase that belongs to the MAP kinase kinase family. This kinase is known to 
play a critical role in mitogen growth factor signal transduction and mutations in this gene 




defects, mental retardation, and distinctive facial features similar to those found in Noonan 
syndrome. The inhibition or degradation of this kinase is also found to be involved in the 
pathogenesis of Yersinia and anthrax. A pseudogene (LOC407835), which is located on 
chromosome 7, has been identified for this gene and was also shown to have altered 
expression by LRP1B (http://www.ncbi.nlm.nih.gov/gene/5605). The protein encoded by 
SLC38A5 (solute carrier family 38, member 5), located on the X-chromosome at p11.23, is a 
system N sodium-coupled amino acid transporter involved in the transfer of glutamine, 
asparagine, histidine, serine, alanine, and glycine. The encoded protein does not transport 
charged amino acids, imino acids, or N-alkylated amino acids 
(http://www.ncbi.nlm.nih.gov/gene/92745).  
A possible mechanism for the increased rate of aging that we observe in association 
with variation in our most significant SNP (rs10496861) that follows our evolutionary 
expectations is that the minor allele causes a reduction in LRP1B’s endocytosis capability. 
Endocytosis and autophagy work as partners to take in and break up molecules. Both pathways 
are highly conserved as is gene LRP1B, demonstrated by the presence of homologues in six 
other organisms. Constitutive autophagy has a housekeeping role and is essential for survival, 
development and metabolic regulation (Markaki, 2011). Research has also shown that 
autophagy is also responsive to stress and can degrade damaged proteins and organelles, 
oxidized lipids and intracellular pathogens and that defects in the autophagic degradation 
system have been linked to disease pathogenesis and aging. Different signaling pathways 
converge on autophagy to regulate lifespan in diverse organisms and autophagy is a critical 




Another study showed that genetic inhibition of autophagy induces degenerative 
changes in mammalian tissues that resemble those associated with aging, and normal and 
pathological aging are often associated with a reduced autophagic potential (Rubinsztein, 
2011). This study also showed that pharmacological or genetic manipulations that increase life 
span in model organisms often stimulate autophagy, and its inhibition compromises the 
longevity-promoting effects of caloric restriction, Sirtuin 1 activation, inhibition of 
insulin/insulin growth factor signaling, or the administration of rapamycin, resveratrol, or 
spermidine, which could be insightful for considering future targets. 
With GWAS there is always a chance that the findings are false positives, which is very 
likely the case for rs9472826 and rs17476005 in the risk age difference meta-results. SNP 
rs9472826 has a MAF of only 0.6% in our sample and this SNP was only present in two of the 
cohorts (n=7,242 with SardiNIA and TwinsUK combined). This suggests that only 44 copies of 
the minor allele are present in the entire sample. SNP rs17476005 is even rarer with a MAF of 
0.08% (9 copies out of the 11,319 individuals from ARIC and TwinsUK). With such a small 
number of copies in the sample, the results could be highly affected by error rates in both 
genotype calling and imputation, which are less accurate for rare alleles.  
The findings for the top SNP (rs10496861) which was genome-wide significant and 
located in the LRP1B gene appear to be quite robust. The MAF is 34%, which is well in the range 
for effects we would expect to indentify using GWAS. Also, we saw similar direction of 
association in all four cohorts (n=19,860) and there was no significant heterogeneity found in 




characteristic spike on a LocusZoom plot (Figure 3.3), showing that although less significant, our 
analysis picked up nearby SNPs in linkage disequilibrium with our SNP.  
The current study was limited to individuals of European descent to remove potential 
bias from inadequately accounting for population admixture, but it does limit the 
generalizability of the findings. Future work should be done investigating this gene and 
polymorphism in other ancestry groups. Another potential issue with the current work was 
demonstrated in the QQ plot for the risk age difference in FHS, where GC values were 0.91. This 
cohort created their imputed data set from samples that were genotyped on two different 
chips. Because of the direction of bias in the FHS sample, we would expect to find less 
significant results and therefore this should not be a major limitation in interpreting any 
significant findings. The SardiNIA cohort also had samples genotyped on different samples, but 
took great care in imputation, employing the family information, as described by Burdick, et.al.  
There are limitations in this work due to how the traits were defined, as well. It is 
possible that one of the physiologic factors used to predict age or mortality risk may be driving 
our findings. Since the GWAS results from the CKD-Gen studies are publically available 
(https://intramural.nhlbi.nih.gov/labs/CF/Pages/CKDGenConsortium.aspx), I was able to verify 
that genome-wide significant SNP was not significant in their kidney-specific analyses. In 
particular, the p-value for the odds of CKD for SNP rs10496861 was 0.7728 and for the 
continuous measure of eGFR the p-value was 0.5380.  
Analysis is currently underway to replicate the findings from this study, focusing on 




consistent replication can greatly improve the credibility of a genotype-phenotype association, 
there is still a chance it may not eliminate spurious associations due to biases shared by many 
studies (Kraft, 2009). If these findings do replicate and the bioinformatics hypotheses are 
plausible, then a next step would be to begin looking for the causal variant. This may be 
accomplished by accessing publically available data from the Exome Sequencing Project 
(https://esp.gs.washington.edu/drupal/), which is available from dbGaP. In instances where this 
data will not be suitable, a multi-pronged approach will be needed. Due to the fact that our 
most significant SNP is located in an intron, we would want to sequence the surrounding exons, 
including 50 bp on each side of the exons to clearly capture the intron/exon boundaries. If 
nothing if found within the immediate range then targeted sequencing of the entire gene may 
be in order, being sure to include possible promoter regions in the 2000 bp at the 5’ end. 
There are times when even such targeting sequencing is unable to generate hypotheses 
for the biological processes taking place and then one would need to start considering epi-
genetic factors, such as methylation or histone modification, and consider the role of gene by 
environment interactions, or regulatory mechanisms. 
The findings of this study have demonstrated that aging can be investigated in cohorts 
of varying ages and not restricted to the very elderly or need to be based on survival. An 
association between a polymorphism in the LRP1B gene and the difference in predicted age and 
age reached genome-wide significance and is supported by a previous study investigating 
successful aging. Bioinformatics investigation of this SNP has shown it to alter expression levels 




p<0.0001 Replication work and specific investigations into determining the causal variant are 
underway. If replication of this SNP is successful, it could be a target for determining an 
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Table 3.1: Meta-analysis of Difference between Predicted Age and Age in 20,000 Individuals of 
European Descent, Adjusted for Age. 
Locus Chr 
SNPs in Region 
in Significance 
Range 
Lead SNP Alleles/MAF Effect Size P 
Direction of 
association* 
        
Genome-wide Significant: P < 5 x 10-8 
LRP1B 2 1 rs10496861 T/G/0.34 +0.28 5.78E-09 ++++ 
        
Marginally Significant:  5 x 10-8< P < 5 x 10-7 
LRP1B 2 1 rs6732847 T/C/0.34 +0.16 3.94E-07 ++++ 
ERC2 3 1 rs1167245 T/C/0.46 +0.20 2.35E-07 ++++ 
PSD3 8 1 rs335222 A/C/0.04 -0.80 2.31E-07 ?--- 
OTOGL 12 1 rs10778728 C/G/0.36 +0.21 1.80E-07 ++++ 
KLHL1 13 1 rs2154199 G/A/0.04 +0.46 4.21E-07 ++++ 
MDGA2 14 2 rs1683210 T/C/0.04 +0.54 1.01E-07 ++++ 
NCAM2 21 7 rs1786357 G/A/0.16 +0.33 7.64E-08 ++++ 
        
Suggestive for Replication: 5 x 10-7 < P < 5 x 10-6 
MTOR 1 3 rs3765897 G/A/0.06 +2.07 5.14E-07 +??+ 
EDEM1 3 1 rs17043984 A/G/0.02 +0.60 1.12E-06 ++++ 
CPNE4 3 1 rs16837395 C/G/0.42 +0.22 2.07E-06 ++++ 
SI 3 1 rs12630444 G/T/0.01 -0.77 2.82E-06 ---- 
LPP 3 1 rs9820072 T/A/0.43 +0.07 3.12E-06 +?+? 
CPEB2 4 1 rs218819 G/A/0.03 +0.79 3.31E-06 +??+ 
NUDT12 5 4 rs7702688 A/C/0.03 +0.59 2.89E-06 ++++ 
HLA-L 6 1 rs3094078 A/T/0.09 +0.48 1.58E-06 ++++ 
C6orf105 6 1 rs4140558 T/C/0.28 +0.07 1.16E-06 +++? 
PHACTR1 6 1 rs2327591 T/C/0.10 +0.38 2.74E-06 ++++ 
EYA4  6 1 rs2184784 A/C/0.13 +0.37 8.89E-07 ++++ 
IMMP2L 7 1 rs6968496 C/T/0.24 +0.26 7.11E-07 ++++ 
FBXO25 8 2 rs17737960 C/G/0.07 +0.38 3.00E-06 ++++ 
NKAIN3 8 1 rs10099792 G/A/0.10 +0.35 1.67E-06 ++++ 
IL33 9 1 rs13284060 C/A/0.07 +0.39 1.89E-06 ++++ 
KDM4C 9 4 rs4742295 A/C/0.03 -0.58 5.27E-07 ---- 
TMEM38B 9 1 rs3010957 G/A/0.03 +0.47 3.27E-06 ++++ 
MUSK 9 1 rs2846447 G/C/0.20 +0.28 7.70E-07 ++++ 
GRID1 10 1 rs17106322 T/C/0.03 +0.57 7.97E-07 ++++ 
ADAM12 10 1 rs4559596 T/C/0.43 +0.21 1.46E-06 ++++ 
ENDOD1 11 2 rs626246 A/C/0.16 +0.33 1.01E-06 ++++ 
KLHL1 13 1 rs9529821 A/T/0.04 +0.35 2.75E-06 ++++ 
MDGA2 14 1 rs1769488 A/G/0.04 +0.44 1.45E-06 ++++ 
WSCD1 17 1 rs12942336 G/C/0.05 +0.40 4.06E-06 ++++ 
NCAM2 21 20 rs1786368 A/G/0.16 +0.30 6.16E-07 ++++ 





Table 3.2: Meta-analysis of Difference between Risk Age and Age in 20,000 Individuals of 
European Descent, Adjusted for Age. 
Locus Chr 
SNPs in Region 
in Significance 
Range 
Lead SNP Alleles/MAF Effect Size P 
Direction of 
association* 
        
Genome-wide Significant: P < 5 x 10-8 
PLA2G7 6 1 rs9472826 C/T/0.006 +12.0 4.17E-09 +??+ 
        
Marginally Significant:  5 x 10-8< P < 5 x 10-7 
BAI3 6 1 rs17476005 G/A/0.0008 -10.6 3.26E-07 ??-- 
        
Suggestive for Replication: 5 x 10-7 < P < 5 x 10-6 
ASB3/ 
CHAC2 
2 1 rs6735011 C/T/0.35 +0.31 8.98E-07 ++++ 
GABRA1 5 1 rs1531263 G/A/0.49 -0.31 4.81E-06 ---? 
ACO1/ 
MIR873 
9 1 rs10738859 G/T/0.003 -2.6 7.18E-07 ---- 
LOC286370 9 1 rs4744117 A/G/0.34 +0.32 3.54E-06 ?+++ 
C12orf10 12 1 rs4759054 C/T/0.008 +4.5 8.01E-07 +??+ 
CMKLR1 12 1 rs11113865 A/G/0.07 +.56 4.46E-06 ++++ 
SLC14A2 18 3 rs1462152 C/T/0.02 -0.85 5.48E-07 ---- 
ST8SIA3/ 
ONECUT2 
18 9 rs4801093 A/C/0.24 +0.33 1.75E-06 ++++ 





Figure 3.1: QQ plots of Difference between Predicted Age and Age, Adjusted for Age, by Cohort 
 
A. ARIC      B. Framingham 
 
 
C. SardiNIA     D. TwinsUK 









Figure 3.2: QQ plots of Difference between Risk Age and Age, Adjusted for Age, by Cohort 
 
A. ARIC      B.  Framingham 
      
C.  SardiNIA     D.  TwinsUK 





Figure 3.3: Locus Zoom Plot of Gene LRP1B on Chromosome 2 for Predicted Age Difference, 









Figure 3.4: Locus Zoom Plot Chromosome 21, Positions 20.7 to 21.3 Mb, for Predicted Age 








Figure 3.5: Locus Zoom plot of Chromosome 18, position 52.7 to 53.5 Mb for Difference 






Figure 3.6: Locus Zoom plot of Chromosome 18, position 39.9 to 41.6 Mb for Difference 


























Table S3.1: Summary of Study Design and Sample QC, by Cohort 
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Prevalence of chronic kidney disease in the SardiNIA study cohort and 




Universal concern about chronic kidney disease (CKD) and renal failure (National Kidney 
Foundation, 2002, Levey et.al, 2005, Levey et.al, 2007) has been expressed over geographical 
differences in CKD prevalence (Zhang, et.al, 2008, Zoccali, et.al, 2010).  However, only a small 
(though increasing) number of large, adequately powered studies have estimated CKD 
prevalence in general populations. The “template” for such studies is the National Health and 
Nutrition Examination Surveys (NHANES) (Coresh, et.al, 2007), which showed an alarming 
increase of CKD prevalence during the last two decades in the USA. Other surveys in Europe 
(Nynke, 2011, Hallan et.al, 2011, Gambaro, et.al, 2010, Viktorsdottir, et.al, 2005, Wetzels, et.al, 
2007, Cirillo, et.al, 2006) and developing countries (Zhang, et.al, 2008, Zhang, et.al, 2012, 




explained by differences in the prevalence of risk factors such as diabetes, hypertension, 
obesity, and atherosclerosis; but other factors (Levey and Coresh, 2012) can also influence 
prevalence.  In addition to epidemiological and hormonal influences, specific genetic loci were 
recently demonstrated to be significantly associated with estimated glomerular filtration rate 
(eGFR) and with end stage renal disease (ESRD) in large genome-wide association studies of 
individuals of European descent (Böger, et.al, 2011, Köttgen, et.al, 2009).  
General decline in eGFR is in fact a long-established feature of aging (Glassock and 
Winearls, 2008), but some groups of individuals may show a more rapid loss of renal function. 
How much clinical and genetic conditions influence decline of eGFR has been largely 
conjectural. Therefore, we investigated the clinical, epidemiological, and genetic factors that 
may influence both cross-sectional and longitudinal renal function in a well-powered Sardinian 
founder population cohort (SardiNIA study).  In particular, given the recent success in finding 




4.2.1 Study Design 
 
The SardiNIA study, which began in 2001, has measured > 300 traits (endophenotypes, 
quantitative risk-related genetic, and environmental factors) that can be scored on a 
continuous scale for both epidemiological and genetic analyses.  The sample was drawn from 




province in eastern Sardinia (Pilia, et.al, 2006). In 2002, letters were sent to all residents inviting 
them to participate.  About 56% (n=6,162) had initial visits. The recruited cohort, ranging from 
14 to 102 years of age, is representative of the overall age distribution of the region in 2002, 
with a somewhat greater number of females. Visits were repeated approximately every three 
years and data from two additional visits have been collected, with 5,204 individuals 
completing a visit during the third to sixth year of the project, and 4,842 completing a visit 
during the seventh to ninth years. A total of 4,074 individuals had three visits, with a total 
average follow-up of seven years. 
 
4.2.2 Screening and follow-up  
 
Participants were interviewed during the first visit to collect detailed socio-demographic 
information, medical and family history, lifestyle, health behaviors (smoking, drinking, coffee 
intake, etc.), and medications taken. Anthropometric measures (height, weight, and waist 
circumference) and resting blood pressure were determined. Blood samples were collected by 
venipuncture after an overnight fast of at least 12 h at each visit.  Urine specimens were only 
collected at the third visit, in 95% of the participants. Blood tests included serum creatinine, 
blood urea nitrogen [BUN], uric acid, glucose, hemoglobin A1c (HbA1c), and lipid levels. At the 







Diabetics were defined according to the guidelines of the American Diabetes Association 
as individuals with either  HbA1c ≥ 6.5 %, or fasting plasma glucose (no caloric intake for at least 
8 h) ≥ 126 mg/dl (7.0 mmol/L), or on anti-diabetic therapy, or when they reported a diagnosis of 
diabetes.  Blood pressure (BP) was measured using a calibrated desktop sphygmomanometer 
after at least 5 minutes of supine rest. BP was measured three times at intervals of at least 5 
minutes, and the reported BP was the average of the last two measurements. Volunteers were 
classified as hypertensive when BP was ≥ 140 mmHg systolic or ≥ 90 mmHg diastolic, or when 
they reported taking antihypertensive medication. Obesity was defined as BMI (body mass 
index) ≥ 30 kg/m2, according to the World Health Organization’s definition. Abdominal 
circumference was considered high when it was >94 cm for men and >80 cm for women.  
Metabolic syndrome was defined according to the International Diabetes Federation (IDF) 
guidelines (Alberti, et.al, 2006).   
Participants whose albuminuria ranged from 3 to 30 mg/dl and whose proteinuria on a 
urinary spot test was < 30 mg/dl were classified as microalbuminuric, while individuals with 
proteinuria > 30 mg/dl at urinary spot test classified were classified as having 
macroalbuminuria. Cigarette smoking was defined as at least 10 cigarettes a day for a year. 
Previous cardiovascular (CV) events included coronary heart disease, heart attack, heart failure, 
or stroke, and were self-reported. Total cholesterol ≥ 200 mg/dl, triglycerides ≥ 130 mg/dl, LDL 




women and ≥ 7 mg/dl (420 µmol/L) for men were considered high. HDL cholesterol (HDL-C) < 
40 mg/dl for men and < 50 mg/dl for women was considered low.  
 
4.2.4 Genotype Data 
 
Genome-wide markers assayed on a combination of Affymetrix platforms (500K and 1.0) 
(http://www.affymetrix.com ) and imputed using HapMap2 samples as a reference, were used 
to calculate a genetic risk score from a list of 18 published loci found to be associated with CKD 
(Köttgen, et.al, 2012, Böger, et.al, 2011). Sixteen of the loci were available for analysis and 
ultimately 13 loci that were found to have the same direction of association with CKD in the 
SardiNIA sample were included: rs13538, rs347685, rs626277, rs881858, rs1731274, rs4744712, 
rs11959928, rs17319721, rs1260326, rs10109414, rs13038305, rs2467853, and rs12917707 
(Table 3). For each locus, dosages were coded so that a value of 0 indicated the presence of no 
risk alleles, 1 indicated the presence of one risk allele, and 2 indicated the presence of two risk 
alleles. Dosages were added for the 13 loci to create a composite measure with a possible 
range of 0-26. More complicated genetic risk scores were explored, employing weights based 
on their strength of association with each outcome. These scores yielded smaller p-values in the 
association models, but for ease of being able to interpret the risk per 1 additional risk allele, 






4.2.5 CKD classification and measures of kidney function 
 
CKD was defined as eGFR <60 mL/min/1.73 m2 and/or eGFR >60 ml/min/1.73 m2 with 
kidney damage, and was staged according to the KDOQI classification (Levey, et.al, 2005). 
Kidney damage was quantified by albuminuria (micro or macro), and decreased kidney function 
was quantified by eGFR assessed by serum creatinine (sCr) concentrations (Levey, et.al, 2005). 
The Chronic Kidney Disease Epidemiology Collaboration (CKD-Epi) formula was employed in all 
association models because it is considered to be best to estimate GFR in general population-
cohort studies (Wieneke, et.al, 2010). We also did estimation of GFR with MDRD 175 study 
equation to facilitate comparisons with the other surveys. 
 
4.2.6 Calibration of serum creatinine 
 
Measurements of sCr in the SardiNIA Laboratory (NIALab) were performed with a kinetic 
alkaline picrate assay at the first and third visits, but using different instruments, a Bayer 
Express Plus Chemistry Analyzer at first visit and a Biosystem A25 Chemistry analyzer at third 
visit. Calibration was done (Selvin, et.al, 2007) to estimate correctly the prevalence of kidney 
disease in the study cohort, to assess rates of change in kidney function, and to compare the 
data to other surveys. Calibration was carried out by assaying 109 randomly chosen, thawed 
samples from the first visit at the Central Laboratory of the Brotzu Hospital (CLB), Cagliari, Italy, 
where sCr measurements were performed with an Olympus analyzer (Olympus Mishima Co., 
Ltd., Shizuoka, Japan), using Jaffe’s kinetic method. The creatinine concentration for the serum 




A total of 63 randomly chosen specimens were also sent from the CLB to the NIA Lab for 
the measurement of sCr values using the same instrument that had been used for the third visit 
analysis. Extreme outliers (difference > 3 standard deviations, SDs, from the mean) were 
excluded because they would not contribute useful information to the calibration. Deming 
linear regression (Y = CCRL on X = original serum creatinine) was conducted for each survey to 
correct the regression models for measurement error (Selvin, et.al, 2007).  
Two calibration equations were generated from the results and applied accordingly: 
1) First/second visit: y (CLB) = -0.107+ 1.066*Creatinine NIALab 
2) Third visit: y (CLB) = -0.195+ 1.0977*Creatinine NIALab 
After standardization, we compared sCr values in subgroups of individuals in the same age 
range (20- 40 yr) and found that no statistically significant differences (Figure S4.1). 
 
4.2.7 Statistical Analyses 
 
Quantitative data are presented as the mean ± SD, and categorical data are presented 
as percentages. Differences between groups were examined using chi-square statistics for 
categorical variables.  
The unadjusted odds ratios (OR) between risk factors and CKD were calculated using 
univariate logistic regression analysis, whereas the adjusted OR was calculated by multivariable 
logistic regression analysis, accounting for family membership by using generalized estimating 




were significant (p<0.10) in univariate regression models were entered into a full multivariable 
model. In instances in which variables were known to be strongly correlated to one another 
(e.g., glucose and diabetes) only the one with the strongest association was included in the final 
model. Final multivariable models included predictors that were significant at the p<0.10 level. 
Because it is possible that variable that were not significant in the univariate models could 
become significant predictors in the multivariable models (Simpson’s Paradox), we examined all 
combinations of multivariable models and this was not found to be the case. We evaluated 
both the continuous and categorical variables, and since results were very similar, the 
categorical variables are shown for ease of interpretation. 
 
4.2.8 Definition of Decline in eGFR 
Changes in eGFR during the study were assessed in individuals for whom measurements 
at all three visits were available. Linear regression was employed to determine the slope for 
each individual. These models imposed a linear rate of decline on each individual, which was a 
close estimation for most individuals (Figure S4.1) and allowed for a single value estimate for 
use in later association models. Linear mixed models, accounting for family membership as a 
repeated variable with compound symmetry covariance, were used to examine the association 
between known risk factors (including a genetic risk score) and change in eGFR (slope).  
Individuals were defined as having a “fast decline” in eGFR if their slope was steeper 
than -13.18 ml/min over the 6 years of follow-up, as this value indicated that these individuals 




examined by logistic regression to determine their association with classification as “fast 
decline”. All analyses were performed using SAS 9.3 software (SAS, Cary NC).  
 
4.2.9 Methodological considerations for cross study comparisons  
 
To date, our cohort is one of the largest European cohorts to have been investigated 
using the CKD-Epi eGFR formula. For the first time, a genetic risk score for CKD was tested in a 
general population. The SardiNIA study cohort differs in ethnicity from the NHANES, HUNT II, 
Beijing, and INCIPE cohorts. Like the HUNT II and NHANES studies, we enrolled a large, 
representative sample of pedigrees from the general population and achieved high 
participation and completion rates. In order to optimize the comparison of our cohort with the 
HUNT II and NHANES populations we used the same eGFR formulas and stratified the data by 
age. Therefore, prevalence rates of CKD can be compared, although the very low prevalence of 
CKD stage 4 and 5 described here may be biased by an underestimation of sicker individuals, 
whose participation in the study tended to be curtailed.   
Calibration of sCr assays included a correction factor similar to that employed in the 
NHANES and HUNT II analyses (Selvin, et.al, 2007, Hallan, et.al, 2006). With this correction, the 
MDRD 175 formula and the CKD-Epi formula can be considered unbiased in the cohort. The 
precision of the CKD-Epi equation is limited as compared to measured GFR, but the formula 
corrects the bias of previous formulas in the classification of normal and mildly decreased eGFR 
groups (Skali, et.al, 2011).  Using the MDRD study equation we avoided biases comparing our 




The SardiNIA project was not designed as an epidemiological study of  CKD, and in 
addition to the lack of determinations of micro-macroalbuminuria and ACR ratio in the first visit 
(see above), quantitative determination of microalbuminuria  was evaluated only qualitatively 
by dipstick (albustick), and only once.  Consequently, the prevalence of micro-macro-
albuminuria and stages 1 and 2 CKD may have been overestimated.  In order to  reduce any 
overestimation of albuminuria, which is the strongest risk factor for CKD progression and thus 
for the development of cardiovascular disease(Sarnak, et.al, 2003), subjects were defined as 
being affected by microalbuminuria when values were  greater than 3 mg/dl, in both genders. 
Encouragingly, the prevalence of persistent microalbuminuria was   also higher than 
macroalbuminuria in CKD stages 1 and 2 in the NHANES study (Coresh, et.al, 2007). 
 
4.3 Results 
4.3.1 General Demographic Characteristics of the SardiNIA study cohort 
 
This cohort was representative of the regional population in Ogliastra with regard to 
mean age (43.7, SD 17.6), gender (58% female), and age groups, as per the National Census 
data shown in Figure S4.2 (Pilia, et.al, 2006). At the third visit, after a median of seven years of 
follow up, 4,842 individuals were examined. As shown in Table 4.1, from the first to the third 






4.3.2 Longitudinal renal function evaluation   
 
As expected from the increasing age of the cohort, mean eGFR was lower at the third 
visit in the whole population: 98.6 ml/min (SE 19.3) compared to the first visit 104.6 ml/min (SE 
20.7, p= 0.001). Therefore individuals in the normal renal function group decreased while 
individuals in the mild, moderate, and severe groups increased (Figure 4.1).  The average 
decline in renal function evaluated by eGFR during the follow-up period was approximately 1 
ml/min/year among the 4,074 individuals that completed all three visits (Figure 4.2). 
 
4.3.3 Prevalence of albuminuria and CKD 
 
We evaluated the prevalence of CKD at the third visit. The proportions of individuals 
with micro- and macro-albuminuria were 9.5 % and 3.4%, respectively. The overall estimate of 
CKD stages 1 to 5 was 14.5%. The specific prevalence of CKD for each stage was: 7.4% for CKD 
stage 1,  4.1% for CKD stage 2,  2.9% for CKD stage 3, 0.07% for CKD stage 4, and 0.05 for CKD 
stage 5 (Figure 4.1). The overall prevalence of CKD among men was 12.9% whereas it was 15.4% 
among women (Table S4.1). The general trend toward higher prevalence of CKD stages 1 and 2 
over time differed among age categories. Consistent with expected aging trends, the proportion 
of individuals in stage 1 was higher in the younger age group, i.e., below 30 years of age (> 
10%), compared to 7.0% in the 30-39 year-old group and 5% in the 40-49 year-old group (Table 
S4.1). Total prevalence of CKD increased among age categories from 12.7% in the 50-59 year-
old group, to 16.3% in the 60-69 group, to 36.5% in the 70-79 group, to 48.1% in the over eighty 




hypertension (27.9%), high BMI (22.8%), hyperuricemia (28.4%), and metabolic syndrome 
(27.9%). The lowest CKD prevalence, i.e., 8.5%, was observed in individuals who had none of 
the risk factors listed above (Table S4.1). 
 
4.3.4 Comparison of SardiNIA study results with NHANES (1988-1994 and 1999-2004), HUNT II 
and Beijing study results  
 
To compare our population to the other populations we used CKD prevalence data 
obtained by the MDRD 175 formula stratified by age. SardiNIA’s CKD prevalence was about the 
same as NHANES (16.1 vs 16.5) and Beijing (12.4 vs 11.2), higher than in the HUNT II (16.1 vs 
11.2), and lower than NHANES 1999-2004 (16.8 vs 20.3), although these were next tested for 
statistically significant differences (Table 4.2).    
Similar results can are seen by taking into account kidney function, grouped as normal, 
mildly reduced, moderately reduced, and severely reduced, and stratifying by age.   The 
Sardinian cohort included significantly more individuals with normal renal function than 
Americans (54.4% vs 51.9% in NHANES 1988-1994 and 52.7% vs 40.7% in NHANES 1999-2004) 
and fewer than in the  HUNT II (52.6% vs 56.7%) and Beijing (56.3% vs 64.7%) studies. The 
opposite trend was evident for mildly reduced and moderately reduced eGFR, and no 






4.3.5 Risk factors associated with CKD 
 
In univariate analysis, we evaluated 15 variables and found that all of them were 
significantly associated with the presence of CKD, except for smoking, major lipid profile, and 
cortical thickness. In the final reduced multivariable model, older age (per 10 years, OR= 1.31), 
female gender (OR= 1.28), diabetes (OR=1.48), and genetic risk score (per 1 risk allele, OR = 
1.07) were independently associated with CKD. High uric acid (OR= 1.28, p= 0.06) and abnormal 
kidney length (OR= 1.26, p= 0.06) showed an association trend with CKD (Table 4.3).  
4.3.6 Risk factors associated with change in eGFR 
 
In univariate analysis, only smoking, low HDL-C, and cortical thickness were not 
significantly associated with decline in eGFR. In the final reduced multivariable model, baseline 
eGFR (per 10 ml/min, - 0.52 ml/min), age (-3,5 ml/ min), male gender (1.23 ml/ min), diabetes (-
3.13 ml/ min), hypertension (-1.69 ml/ min), high uric acid (-1.36 ml/ min), and genetic risk 
score (per 1 risk allele, - 0.23 ml/min) were associated with a change in  eGFR (data are 
expressed in ml/ min per 10 years) (Table 4.4). 
In univariate analysis of the dichotomous outcome of fast decline of eGFR (-2.3 
ml/min/year) and the predictors listed above as the independent variables, only smoking, lipid 
profile and cortical thickness were not significant in the multivariable model, whereas previous 
cardiac disease only showed marginally significant positive trend (p=0.06). In the final reduced 
multivariable model, age (per 10 years, OR= 1.67), female gender (OR=1.39), hypertension 




significantly independently associated with a faster decline of eGFR, whereas diabetes (p=0.11) 




Assessed for the first time in a European founder population, CKD prevalence and 
geographical variability have been confirmed. It is likely the rapid increase of traditional risk 
factors has contributed to the high prevalence of early stages of CKD.  We also present 
evidence for additional clinical risk factors, especially hyperuricemia and ultrasound renal 
length, but not renal cortical thickness. This result counters to what has been reported in a 
small group of patients with advanced stages of CKD and GFR estimated by Cockcroft-Gault and 
MDRD 186 formulas (Beland, et.al, 2010). Instead, in our work, these two parameters have 
been tested for the first time as risk factors in such large sample of pedigrees from a general 
population versus early stages of CKD and with GFR estimated by CKD-Epi formula. For the first 
time we have also shown that a genetic renal risk score supplies an independent risk factor for 
CKD and fast eGFR decline.  
The cross-sectional CKD prevalence was high (14.6%) in the SardiNIA cohort, although 
the population was relatively young (mean age 49.8 ys). Early stages of CKD were the most 
represented (CKD 1 + 2: 11.3%), which corresponds to the high prevalence of proteinuria 
(12.8% in the whole cohort). The prevalence estimate might be reduced if we had used ACR to 
detect proteinuria and did urinalysis more than once; but it seems more likely that the high 




more American lifestyle/diet has been adopted, mainly in the last 10 years (Table 4.1).  
Furthermore, based on the level of early CKD, the percentage of individuals with eGFR < 60 
ml/min is expected to rise in the future (and may already be underestimated because patients 
affected by chronic disease tend to participate less in repeated follow-up visits). Further 
understanding of the interactions between obesity, metabolic syndrome and CKD could 
represent a potential strategy to reduce end stage renal disease (ESRD) in the future.    
In addition to using the CKD-Epi formula, as recommended (Skali, et.al, 2011), we also 
applied the MDRD 175 formula to compare SardiNIA to other large cross-sectional CKD studies. 
Accepting the first-order accuracy of overall estimates, all the populations compared showed a 
greater CKD prevalence in females (15.4%) than in males (12.9%).  Data stratified by age 
showed CKD prevalence in the SardiNIA study similar to to the comparably rural population in 
Beijing – 2008 (12.4% vs 11.2%) and to NHANES 1988-1994 (16.1% vs 16.5%), but lower than 
NHANES 1999-2004 (16.8% vs 20.3%) and higher than HUNT II (16.1% vs 11.2%) (Table 4.2). 
These differences likely result from a combination of factors.  Looking at general risk factors, for 
example, the results are consistent with the higher and increasing prevalence of diabetes and 
metabolic syndrome in the NHANES American population; however, Norwegians have by far 
the highest prevalence of hypertension, often a major cause of ESRD, but had the lowest 
prevalence of CKD.  Differences across the world may also depend on additional parameters 
that have not yet been assessed, including environmental and hormonal factors, genetic 
variation (see below), and even differences in health policy, particularly screening programs 




Longitudinal analysis of data in the 4,074 individuals who performed all 3 visits showed 
an overall reduction in mean eGFR. In a mean of 7 years of follow-up, individuals with normal 
renal function decreased, whilst there was a consistent increase in the prevalence of mildly and 
moderately reduced eGFR.   This was partially expected as a result of aging (Prakash, et.al, 
2009) of the cohort with the increased prevalence of clinical risk factors.  In particular, diabetes, 
a major cause of ESRD in developed countries, showed an increase of almost 100%. It was an 
independent risk factor for CKD and its presence was associated with a significant additional 
change in eGFR (-3.13 ml/m’/yr). However it was not a predictor of fast eGFR decline, probably 
because of the high prevalence of CKD stage 1; in early stages of diabetic nephropathy 
glomerular hyperfiltration is observed, resulting in a misleading “improvement” of renal 
function. 
Also, Obesity had an increasingly high prevalence (18.2%), especially compared to the 
Italian mainland population (8-10%) (Eurostat, 2011). As suggested by Zoccali et al, obesity can 
amplify the cost of CKD, hypertension, diabetes, and cardiovascular disease consuming a large 
fraction of healthcare resources (Zocalli, et.al, 2010). However, its correlation with CKD did not 
remain significant in multivariable analysis. Hypertension, the other main cause of ESRD in 
developed countries. Hypertension increased in prevalence weakly and was associated with fast 
eGFR decline. However hypertension was not an independently significant risk factor for CKD. 
This is again most likely because CKD stages 1-2, the most prevalent in SardiNIA, are 
characteristically associated wth proteinuric conditions like diabetes and obesity, whilst 
hypertensive nephroangiosclerosis is associated with more advanced renal damage. Moreover, 




inhibitors (Materson, et.al, 1993), and better control of hypertension might have weakened its 
correlation to CKD. 
Ultrasound renal length, according to other studies and in our experience, is strongly 
associated with CKD when advanced renal damage is present (Sanusi, et.al, 2009). Using a 
restrictive cut-off for renal length (< 10 cm) we observed a correlation with CKD and eGFR 
decline. Hyperuricemia has not been extensively assessed in published surveys, but the 
prevalence was high in SardiNIA.  The correlation of uric acid with CKD and with fast eGFR 
decline was significant, suggesting it as a risk factor. Experimental and clinical studies have 
indicated that elevated uric acid can itself lead to kidney disease without deposition of uric acid 
crystals. Glomerulosclerosis, interstitial fibrosis and arteriolar disease without intrarenal urate 
crystals are the principal lesions in rats with elevated uric acid levels (Kang, et.al, 2002, Mazzali, 
et.al, 2001). Uric acid may thus be implicated in renal disease in human, and lowering its blood 
levels may slow disease progression, especially in patients with hyperuricemia (Mazzali, et.al, 
2001, Siu, et.al, 2006, Kanbay, et.al, 2007).  It remains to be further documented whether uric 
acid is a general independent biomarker of early renal damage and possible prognosis of 
progression (Feig, et.al, 2008). 
For the first time in a study on CKD prevalence and on the longitudinal renal function 
conducted in a general population, we have further tested a risk score to assess the relevance 
of genetic factors. A multivariable model inclusive of traditional risk factors and other measures 
associated with CKD showed that the genetic renal risk score, based on 13 published loci 




additional risk allele had a 7% higher odds of having CKD, a greater decline in eGFR (-0.23, p= 
0.004), and 5% increased odds of fast eGFR decline. Although these estimates are relatively 
modest for 1 additional risk allele, when one takes into account the range of data in the cohort 
(6-24), risk increases are quite substantial: 337% higher odds of CKD, -4.14 greater decline in 
eGFR over 10 years, and 240% higher odds of “fast decline”.  Further work is required to cross-
compare the reproducibility of results in Sardinia and in other ethnicities, and to refine 
predictive models for clinical use based in effect sizes of individual genetic loci. 
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Table 4.1: Demographics and CKD Risk Factors for the SardiNIA Study, by Wave * 
Variable 








or Χ2 p-value 
Wave 1 Wave 2 Wave 3 
Trend Test 
or Χ2 p-value 
Categorical Measures:        
   Age (years, %):         
      < 20 
      20 – 39 
      40 – 59 
      60 – 69 

































   Male (%) 42.6 41.8 42.3 0.64 41.5 41.5 41.5 - 
   Smoking (%) 17.0 21.4 23.7 < 0.0001 17.7 21.9 24.3 < 0.0001 
   Metabolic syndrome (%) 6.3 6.8 13.1 < 0.0001 7.6 9.6 19.3 < 0.0001 
   Obesity (%) 15.7 16.7 18.1 < 0.0001 14.8 16.3 18.6 < 0.0001 
   Large waist (%) 39.6 43.5 49.2 < 0.0001 39.3 43.2 50.1 < 0.0001 
   Diabetes (%) 5.2 7.4 9.1 <0.0001 3.7 6.4 9.2 < 0.0001 
   High glucose (%) 3.8 4.4 6.2 <0.0001 2.7 3.5 6.3 < 0.0001 
   Hypertension (%) 29.9 31.8 32.0 <0.0001 28.1 31.1 34.4 < 0.0001 
   High Blood Pressure (%) 25.5 24.9 22.1 0.22 24.2 24.9 24.5 0.73 
   Previous cardiac disease (%) 4.2 4.7 5.6 < 0.0001 3.56 4.22 5.94 < 0.0001 
   High uric acid (%) 13.2 15.0 16.9 <0.0001 12.0 14.5 17.1 < 0.0001 
   High total cholesterol (%) 56.2 55.7 63.7 < 0.0001 58.1 57.3 65.0 < 0.0001 
   High LDL (%) 66.2 67.2 76.3 < 0.0001 67.6 68.5 78.0 < 0.0001 
   Low HDL (%) 7.0 6.1 19.3 < 0.0001 6.0 5.7 20.1 < 0.0001 
Continuous Measures, mean (sd):        
   Age (years) 43.7 (17.6) 46.9 (16.8) 49.7 (16.3) < 0.0001 43.3 (15.8) 46.7 (15.8) 50.7 (15.8) < 0.0001 
   BMI 25.3 (4.7) 25.6 (4.6) 25.9 (4.7) < 0.0001 25.4 (4.5) 25.6 (4.5) 26.1 (4.7) < 0.0001 
   Waist circumference (cm) 84.8 (13.2) 85.6 (12.5) 87.2 (12.3) < 0.0001 84.5 (12.8) 85.4 (12.4) 87.3 (12.2) < 0.0001 
   Glucose (mg/dl) 90.1 (23.7) 90.8 (23.3) 98.3 (25.0) < 0.0001 88.7 (20.7) 89.9 (21.7) 98.8 (24.6) < 0.0001 
   Sys Blood pressure (mm/Hg) 125.6 (18.6) 124.5 (17.9) 119.4 (26.0) 0.23 124.9 (17.6) 124.6 (17.4) 125.4 (18.9) 0.26 
   Uric Acid () 4.3 (1.5) 4.5 (1.5) 4.6 (1.4) < 0.0001 4.2 (1.4) 4.4 (1.5) 4.6 (1.4) < 0.0001 
   Total Cholesterol (mg/dl) 208.5 (42.2) 206.9 (38.9) 215.3 (40.3) < 0.0001 210.0     41.0 208.0 (38.7) 216.6 (40.0) < 0.0001 
   LDL Cholesterol (mg/dl) 126.8 (35.4) 125.7 (32.7) 135.5 (34.6) < 0.0001 127.8    34.7 126.8 (32.5) 136.9 (34.3) < 0.0001 
   HDL Cholesterol (mg/dl) 64.1 (14.9) 63.0 (13.7) 56.8 (14.1) < 0.0001 64.7    14.8 63.3 (13.5) 56.8 (14.2) < 0.0001 




Kidney Measures:         
   Reduced Length (<  10 cm) - - 18.1 -     
   Reduced Cortical Thick (< 10mm) - - 2.5 -     
   Microalbuminuria (%) - - 9.5 -     
   Macroalbuminuria (%) - - 3.4 -     




Table 4.2: Prevalence of CKD stages and of kidney function categories, stratified by age in SardiNIA study cohort individuals aged 14 years or older based on 
third visit (SardiNIA 3) and compared to  NHANES 1988- 1994 and 1999- 2004, Beijing, and HUNT II populations (glomerular filtration rate estimated by MDRD 
175). 
 Prevalence of CKD (95% CI) 
CKD 1 CKD 2 CKD 3 CKD 4 TOT 





SardiNIA 3 5.6 (4.9- 6.4) 5.7 (5.0-6.5) 4.6 (3.9 – 5.4) 0.1 (0.0- 0.3) 16.1 (14.9 – 17.4) 
NHANES 1988-1994 (14,319) 4.2 (3.9- 4.5) 4.8 (4.4- 5.2) 7.1 (6.7- 7.5) 0.3 (0.2- 0.4) 16.5 (15.8- 17.1) 
SardiNIA 3 5.6 (4.9 – 6.4) 6.0 (5.3 – 6.9) 5.0 (4.3 -5.8) 0.1 (0 – 0.3) 16.8 (15.5 – 18.1) 
NHANES 1999- 2004 (12,216) 4.0 (3.6- 4.3) 5.5 (5.1- 5.9) 10.2 (9.6- 10.8) 0.6 (0.5- 0.8) 20.3 (19.5- 21.1) 
SardiNIA 3 5.5 (4.8- 6.3) 5.9 (5.1 – 6.6) 4.6 (4.0 – 5.4) 0.1 (0.0–0.3) 16.1 (14.9 – 17.4) 
HUNT II (65,181) 3.1 (3.0- 3.2) 3.4 (3.3- 3.5) 4.5 (4.3- 4.7) 0.16 (0.13- 0.19) 11.2 (10.9- 11.5) 
SardiNIA 3 5.5 (4.8- 6.3) 4.5 (3.9- 5.2) 2.4 (2.0- 2.8) 0.1 (0.0- 0.2) 12.4 (11.4- 13.4) 
Beijing(13,925) 5.5 (5.2- 6.0) 3.8 (3.5- 4.2) 1.7 (1.5- 2.0) 0.1 (0.1- 0.2) 11.2 (10.7- 11.8) 
 Kidney function (MDRD eGFR), mL/min/1.73 m2 
Normal  (≥ 90) % 
Mildly reduced  
(60- 90) % 
Moderately reduced 
(30- 60) % 
Severely reduced  
(15- 30) % 





SardiNIA 3 (4,731) 54.4 (52.2- 56.7) 41.0 (39.1- 42.9) 4.5 (3.8- 5.2) 0.2 (0.1- 0.4) 
NHANES 1988-1994 (15,488) 51.9 (50.7 – 53.1) 42.4 (41.3- 43.5) 5.4 (5.0- 5.8) 0.21 (0.14- 0.29) 
SardiNIA 3 52.7 (50.6- 54.9) 42.3 (40.4- 44.2) 4.9 (4.2- 5.7) 0.2 (0.1- 0.4) 
NHANES 1999- 2004 (13,233) 40.7 (39.6- 41.8) 51.2 (50.0- 52.5) 7.7 (7.2- 8.2) 0.35 (0.25- 0.46) 
SardiNIA 3 52.6 (50.6- 54.7) 42.8 (40.9- 44.7) 4.5 (3.8- 5.2) 0.2 (0.1- 0.3) 
HUNT II (65,181) 56.7 (56.1- 57.3) 38.6 (38.1- 39.1) 4.5 (4.3- 4.7) 0.16 (0.13- 0.19) 
SardiNIA 3 56.3 (54.6- 59.1) 40.9 (39.0- 42.8) 2.3 (1.9- 2.7) 0.1 (0.0- 0.2) 












2.891.50 1.28 2.90 0.08












Wave 1 Wave 2 Wave 3 Wave 3
NHANES Definition
Normal Function (eGFR ≥ 90 ml/min, %)
Mildly Reduced (60 ≤ eGFR < 90 ml/min, %)
Moderately Reduced (30 ≤ eGFR < 60 ml/min, %)
 Severely Reducted (eGFR < 30 ml/min, %)
eGFR only Definition
Normal Function 
(no albuminuria and 
eGFR > 90 ml/min, %)
Stage 1 CKD               
(albuminuria and eGFR > 90 
ml/min, %)
Stage 2 CKD                     
(albuminuria and eGFR > 60 
ml/min, %)
Stage 3 CKD                             
(30 > eGFR > 60 ml/min, %)
Stage 4 CKD                             
(15 > eGFR > 30 ml/min, %)
Stage 5 CKD                                 









Table 4.3: Previously Identified Genetic Loci used in SardiNIA Risk Score for eGFR, with Univariate Beta Estimate from SardiNIA Data. 
Marker Chr Position 
Risk 
Allele 
Gene SardiNIA β CKD-Gen β Comments 
Identified in Köttgen, 2009 
   rs12917707 16 20,275,191 G UMOD -0.3701 -1.02 
Familial juvenile hyperuricemic nephropathy type 1 (FJHN1) & 
medullary cystic kidney disease type 2 (MCKD2) 
   rs17319721 4 77,587,871 A SHROOM3 -0.4081 -1.01 
A susceptibility gene for kidney disease in an obese mouse model 
of type II diabetes 
   rs2467853 15 43,486,085 G 
SPATA5L1-
GATM 
-1.0190 -1.01 SNPs in region association with renal tumors 
   rs13038305 20 23,558,262 C CST3-CST9 -0.0084 +1.07 
SNPs in region associated with kidney function and endocrine-
related traits 
   rs1731274 8 23,822,264 A STC1 -0.2326 -1.02 May play a role in regulation of renal and intestinal calcium 
     
 
 
Identified in Böger, 2011 
   rs11959928 5 39,375,121 A DAB2 -0.5816 N/A May modulate growth factor/Ras pathways 
   rs626277 13 72,347,446 A DACH1 -0.4470 N/A 
Regulates gene expression and cell fate determination during 
development. Expression of this gene is lost in some forms of 
metastatic cancer, and is correlated with poor prognosis. 
   rs10109414 8 23,750,901 C STC1 -0.3411 N/A May play a role in the regulation of renal and intestinal calcium  
   rs13538 2 73,868,078 A NAT8 -1.7967 N/A 
Specifically expressed in kidney and liver. May affect cell 
adhesion and gastrulation movements. 
   rs1260326 2 27,730,690 C GCKR -0.1417 N/A 
Considered a susceptibility gene candidate for a form of maturity-
onset diabetes of the young (MODY) 
   rs4744712 9 71,434,457 A PIP5K1B -0.4639 N/A May be involved in stable platelet adhesion 
   rs881858 6 43,806,359 A VEGFA -0.2690 N/A 
Mutations in this gene have been associated with proliferative 
and nonproliferative diabetic retinopathy 





Table 4.4: Multivariable Odds Ratios for CKD (NHANES definition) at Visit 3* and Decline in eGFR during study N=4,273 
Measure (yes/no) Odds of CKD Additional change in eGFR 
(ml/min) 
Odds of Fast Decline 
OR (95% CI) P-value Estimate per 10 
year 
P-value OR (95% CI) P-value 
Baseline eGFR (per 10 
ml/min) 
- - -0.52 <0.0001 - - 
Age (per 10 years) 1.31 (1.22 – 1.40) <0.0001 -3.5 <0.0001 1.67 (1.44 – 1.95) <0.0001 
Male (yes/no) 0.72 (0.56 – 0.91) 0.006 1.23 0.0007 0.61 (0.47 – 0.76) <0.0001 
Diabetes (yes/no) 1.48 (1.10 – 2.00) 0.01 -3.13 0.01 1.64 (0.90 – 2.96) 0.11 
Hypertension (yes/no) - - -1.69 0.0003 1.58 (1.17 – 2.12) 0.003 
High uric acid (yes/no) 1.28 (1.00 – 1.67) 0.06 -1.36 0.03 1.97 (1.39 – 2.80) 0.0001 
Abnormal Kidney Length  
   (yes/no) 
1.26 (1.00 – 1.59) 0.06 - - - - 
Genetic Risk Score  
   (per 1 risk allele) 
1.07 (1.03 – 1.12) 0.001 -0.23 0.004 1.05 (1.003 – 1.10) 0.04 













Table S4.1: Comparison of Characteristics by CKD Status and Fast Decline Status 
Variable CKD (n=696) 
No CKD 
(n=4,146) 
Χ2 or T-test p-
value 
eGFR Decline > 
1 SD* (n=551) 
 eGFR Decline ≤ 1 
SD* (n=3,522) 
Χ2 or T-test p-
value 
Categorical Measures:    Categorical Measures:  
   Age (years, %):       
      < 20 
      20 – 39 
      40 – 59 
      60 – 69 























   Male (%) 38.1 43.1 0.01 37.4 42.1 0.04 
   Smoking (%) 25.6 23.4 0.21 15.9 17.9 0.27 
   Metabolic syndrome (%) 30.0 20.1 <0.0001 15.4 9.4 <0.0001 
   Obesity (%) 23.6 17.2 0.0002 17.9 14.3 0.03 
   Large waist (%) 60.5 47.3 <0.0001 46.0 38.2 0.0003 
   Diabetes (%) 15.5 8.0 <0.0001 6.6 3.3 0.0002 
   High glucose (%) 10.6 5.5 <0.0001 5.1 2.3 0.0004 
   Hypertension (%) 44.5 29.9 <0.0001 40.0 26.2 <0.0001 
   High Blood Pressure (%) 28.7 21.0 <0.0001 34.8 22.6 <0.0001 
   Previous cardiac disease (%) 9.5 5.2 0.0003 5.5 3.5 0.03 
   High uric acid (%) 22.0 16.1 0.0004 16.9 11.2 0.0002 
   High total cholesterol (%) 66.3 63.3 0.14 62.6 57.4 0.02 
   High LDL (%) 77.0 76.2 0.66 69.4 67.4 0.35 
   Low HDL (%) 24.7 18.3 0.0002 5.1 6.2 0.32 
Continuous Measures, mean (sd):    Adjusted mean (se of mean): 
   Age (years) 56.0 (17.2) 48.7 (15.9) <0.0001 47.5 (0.50) 42.7 (0.19) <0.0001 
   BMI 26.9 (4.9) 25.7 (4.7) <0.0001 25.9 (0.19) 25.3 (0.07) 0.002 
   Waist circumference (cm) 89.7 (13.2) 86.8 (12.1) <0.0001 85.9 (0.52) 84.2 (0.20) 0.003 
   Glucose (mg/dl) 103.7 (33.5) 97.4 (23.2) <0.0001 92.0 (0.89) 88.3 (0.35) <0.0001 
   Sys Blood pressure (mm/Hg) 122.5 (27.0) 118.2 (25.8) <0.0001 129.5 (0.28) 124.3 (0.72) <0.0001 
   Uric Acid () 4.90 (1.61) 4.58 (1.38) <0.0001 4.42 (0.06) 4.20 (0.02) 0.001 
   Total Cholesterol (mg/dl) 216.1 (41.6) 215.2 (40.1) 0.58 212.1 (1.7) 209.7 (0.66) 0.19 
   LDL Cholesterol (mg/dl) 135.3 (34.8) 135.5 (34.6) 0.88 128.3 (1.5) 127.8 (0.56) 0.74 
   HDL Cholesterol (mg/dl) 56.7 (15.5) 56.9 (13.8) 0.74 64.5 (0.65) 66.2 (0.25) 0.01 
   Triglycerides (mg/dl) 121.4 (82.4) 114.3 (66.8) 0.03 87.5 (3.0) 88.2 (1.2) 0.84 
   Genotype Score 16.51 (2.3) 16.17 (2.3) 0.002 16.4 (0.11) 16.2 (0.04) 0.20 








































 Due to the huge population age shift that the world is currently experiencing, our 
emphasis on disease prevention and management of chronic diseases needs to increase.  In 
2006, almost 500 million people worldwide were 65 and older. By 2030, that total is projected 
to increase to 1 billion, comprising approximately 1 in every 8 of the earth’s inhabitants 
(Dobriansky, et.al., 2007). The most rapid increases in the 65-and-older population are 
occurring in developing countries, which will see a jump of 140 percent by 2030 (Dobriansky, 
et.al., 2007). 
 The number of deaths due to chronic health conditions have superseded the 
number of deaths from communicable causes world-wide, but strikingly so in middle to high-
income countries, such as the United States (CDC, 2013). In high-income countries, 7 out of the 
10 leading causes of death are chronic health conditions and include: heart disease, cancer, 
chronic lower respiratory diseases, stroke/cerebrovascular diseases, Alzheimer's disease, 




In most instances, such as in cardiovascular diseases, diabetes, and kidney disease, 
damage has occurred to the individual’s health before there are clinical symptoms. The CARDIA 
study (Friedman, et.al, 1988) was designed to investigate the development of heart disease in 
black and white adults and has helped bring attention to the need for early recognition and 
intervention for heart disease. They have found that the early intervention can have lasting 
effects years into the future and are more beneficial than intervention at later ages (Lee DH, 
et.al, 2003).  
In order to develop better early recognition and intervention procedures for these 
chronic conditions, we must first understand more about the biological process of aging.  The 
goal of this dissertation was to develop a measure of aging, applicable to a wide range of ages. 
Further, it aimed to determine the genetic basis of this measure, in the hopes that genetic 
biomarkers could be discovered. With such measures available from the time of conception, we 
can begin to assess the potential value of incorporating such genetic risk biomarkers into 
individual-level health care. We are still just beginning to enter the age of personalized genomic 
medicine, but it’s possible that we can begin to incorporate the use of genetic information in 
the care of individual’s with specific diseases, such as chronic kidney disease. Therefore, this 
work also investigated the utility of adding a genetic risk score, along with the accepted clinical 
risk factors for CKD, in the prediction of the decline in kidney function.  
In the second chapter of this dissertation, I constructed two different measures of aging 
that showed moderate heritability. My method was quite novel compared to the approaches 
taken in the past, which have tended to focus on longevity among individuals of very advanced 




measure. Instead of using this approach, I examined adults aged 20 to 90 years of age and 
developed two measures of biologic age which were based on three easily measured 
physiologic indicators of health: serum creatinine, systolic blood pressure, and waist 
circumference. This biologic age was then compared to the individual’s actual age and the 
difference was then assessed for a genetic component. These difference measures can be 
interpreted as the number of years the individual is physically older or younger than the 
average person with the same physiologic measurement values. 
By using only three common measures, I was able to obtain data from five cohorts with 
genetic data on individuals of European ancestry. Data from the ARIC and FHS were obtained 
through dbGaP, while data from SardiNIA, TwinGene, and the TwinsUK came through 
collaboration channels. Data on over 33,000 individuals was available for phenotype 
development.  
The first estimation of biologic age was created by fitting a linear mixed model for each 
cohort to determine each individual’s predicted age, based on their physiologic health measure. 
The second estimate of biologic age incorporated the individual’s risk of mortality predicted by 
the same three physiologic measures. This risk of mortality was then compared to the country 
specific death risk reported from census data. Each individual was assigned a “risk” age that 
was equivalent to the census age that had the equivalent mortality risk.  
Upon investigation of the fitted models by cohort, it became apparent that the age 
distribution of sampled individuals had a strong influence on the ability to obtain the best 




SardiNIA cohort, which has a very large age distribution (included 20-90 year olds in the current 
study), while the mortality risk models were best estimated in cohorts with a larger proportion 
of older individuals that contained more deceased individuals, likely due to the use of 1-year 
mortality estimates.  
In order to assess the traits for a genetic component, heritability analyses were run 
among the related cohorts. Both traits were found to be moderately heritable with the lowest 
estimates seen for the risk age trait in FHS (h2=0.15), where there were few very old individuals, 
and in the SardiNIA study (h2=0.18), where there were only 234 deaths among the sample of 
nearly 6,000 individuals. Heritability estimates were highest for the risk trait among the twin 
studies (h2=0.86-0.90), but may be unreliable, due to the fact that the use of age at entry of the 
study was necessary in the models and twins typically entered at the same age. The predicted 
age differential showed more consistent heritability across the cohorts, especially when 
restricted to individuals between 45-65 years of age (the age range that was present in all 
cohorts), with estimates from 0.25-0.33 in the family pedigrees to 0.60-0.70 in the twin studies.  
In both cases, there was good evidence of a genetic component to the traits, so both 
traits were followed-up using genome-wide association methods, separately for four of the 
cohorts (ARIC, FHS, SardiNIA, and TwinsUK), and these results were meta-analyzed. GWAS is 
currently being run for the TwinGene cohort of approximately 10,000 individuals and these 
results will be used for replication.  
Based on past research of aging and evolutionary theory, we hypothesized that 




First, it would be very plausible to find associations with genes involved in controlling the levels 
of activities, such as DNA repair and antioxidant defense, thus regulating longevity. Secondly, 
genomic loci that contained late-acting deleterious genes that had escaped the force of natural 
selection or that traded benefit at an early age against harm at older ages, termed antagonistic 
pleiotropy, could be expected to be discovered (Kirkwood, 2008).  
One genome-wide significant association was detected in the meta-analysis for the 
predicted age differential and was located within the LRP1B gene on chromosome 2. We found 
that individuals with the minor allele for SNP rs10496861 (MAF=0.34 in our samples) had a 2-3 
year higher difference in predicted age compared to age (p=5.78 x 10-9) than an average 
individual in the same age decade.  
Past research, highlighted in Chapter III, has shown the LRP1B gene to be highly 
pleiotropic. The LRP1B gene is very large (1,900,279 bases) and produces 41 different known 
proteins. Previous studies have found association between this gene and phenotypes such as 
thyroid cancer, where risk was increased due to inactivation of the gene (Prazeres, 2010), and 
insulin-resistance (Burgdorf, 2012). Interestingly, another study on aging, that employed a very 
different study design, also uncovered associations between 3 SNPs in this same gene and 
successful aging without cognitive impairment (Poduslo, et.al, 2009). The SNPs in this previous 
study ranged in distance from our top hit by only 32 to 72 Kb. Bioinformatic investigation of our 
polymorphism showed it to alter expression levels of three other genes, LOC407835, MAP2K2, 




The goal of the research in Chapter IV was to demonstrate the next step in taking 
experimental science findings to application. Working with the longitudinal data from the 
SardiNIA study, I created a genotype risk score for CKD based on loci found to be significantly 
associated with kidney function in two large meta-analyses of GWAS studies (Köttgen, 2009 and 
Böger, 2011). Thirteen loci from the total of eighteen published loci were available in the 
SardiNIA cohort and showed similar direction of association to that of the published meta-
analysis results. For ease of interpretation the thirteen loci were combined in an additive 
manner, so that association results can be interpreted as the effect of having one 1 additional 
risk allele.  
The genetic risk score was significantly associated with current kidney function and also 
future kidney function, after taking into account known clinical risk factors like diabetes and 
hypertension. First, the genetic risk score was predictive of baseline CKD status (OR=1.07 per 
one additional risk allele, p=0.001). More importantly, though, the risk score was also highly 
associated with future decline in kidney function over the study follow-up (β=-0.23 per one 
additional risk allele, over the following 10 years, p=0.004).  The risk score was also significantly 
associated with the odds of being a “fast decliner”, defined as having a decline in kidney 
function that was greater than 1 SD below the mean (or a decline more extreme than 2.3 
ml/min/year, OR=1.05 per one additional risk allele, p=0.04).  
Although these chapters have been presented as a complete project, there is much 
more to be done to make the findings useful in combating chronic disease burden.  GWAS are 
simply the first step in identifying regions of interest associated with specific phenotypes. The 




consequences more fully. Many times the top findings in a GWAS is close to the causal SNP, but 
may not be the exact polymorphism. To accomplish this, the next step should be an analysis of 
the rare variants within and around the LRP1B gene, either through the use of exome chip data, 
exome sequencing data, or potentially imputing the current data on the 1000 Genomes 
reference panel (http://www.1000genomes.org/), which contains rare loci. The Exome 
Sequencing Project data in dbGaP would be a good first place to explore, if the data is available 
to create the two aging traits. 
If publically accessible data is not available, then it would be worthwhile to begin further 
work by sequencing the exons the LRP1B gene both upstream and downstream of the hit. 
Because our variant was found within an intron, it is important to sequence 50 bp outside of 
each exon to be sure that the intron/exon borders are captured. If nothing is found in the 
immediate region, then targeted sequencing of the whole LRP1B gene would be necessary, 
being sure to include the promoter region (usually 2000 bp at the 5’ end). After attempting to 
find the variant with sequencing, if nothing is found then we should being looking into 
epigenetic explanation. There are many inexpensive assays available to quantify methylation of 
the gene. Also, gene-environment interactions and potential regulatory mechanisms should be 
explored.  
When the causal variant is determined, it would be useful to look at the associations 
between the genotypes and expression level of the gene. Since we know that the LRP1B gene is 
an eQTL loci for 3 other genes, expression levels of those genes should also be examined. If a 




one could think about moving into animal models for testing the hypotheses. This should not be 
difficult for this particular gene, since it has homologues in six different well studied species.  
If the true mechanism for the association observed between the LRP1B gene and aging 
is actually related to endocytosis and autophagy as proposed in Chapter III, previous studies 
(Rubinsztein, 2011) have shown that it could be a target for pharmacological or genetic 
manipulations. In model organisms, these manipulations have demonstrated that stimulating 
autophagy often increases life span. Conversely inhibition of autophagy compromises the 
longevity-promoting effects of caloric restriction, Sirtuin 1 activation, inhibition of 
insulin/insulin growth factor signaling, or the administration of rapamycin, resveratrol, or 
spermidine. 
While much work remains to be done to discern the true mechanism and utility of the 
general aging findings discussed in Chapters II and III, the kidney risk score explored in Chapter 
IV could potentially begin to be explored in the clinical setting. Over the past 100 years great 
strides have been made in renal research to allow individuals with little or no kidney function to 
continue to live, but mortality rates remain high for individuals receiving dialysis. 
Until the 1940’s individuals with acute or chronic kidney function had no options and 
often died within days of their kidneys failing. John Abel is credited with having the first idea of 
an artificial kidney in 1914, but it took the personal investment and interest of many individuals 
(Abel, Rountree, Turner, Haas, Hess and McGuigan, Macallum, Lambert and Vogel, Thalheimer, 
Murray, Macneil and the Anthone twins, Kolff, Skeggs and Leonard, Alwall, Kiil, Rosenak and 




Murray, along with Delorme and Thomas, to construct an artificial kidney in Murray's basement 
with a personal investment of $8,000 in 1946 (Schreiner GE, 2000).  
Dialysis is expensive and in the 1960’s communities would often have bake sales and 
fundraisers to help raise money for friends or loved ones in need of dialysis. State coverage for 
care was very limited and the cause began to be picked up by the media. “The coverage 
extended from local weeklies to TV and Life Magazine: "Who shall live and who shall die?" The 
people and their families and their surrogate, the National Kidney Foundation, recognized the 
possibility of a "national" solution, and historically, several things converged at a national 
level.” (Schreiner GE, 2000). In 1972 President Nixon signed the bill that allowed patients with 
end stage renal disease (ESRD) to be classified as disabled and to be eligible for Medicare 
coverage, regardless of age. 
ESRD coverage by Medicare has extended countless lives, but has also created a large 
burden on society, from loss of individuals in the work force to increased Medicare spending. In 
the US, costs for the care of ESRD patients in 2009 rose 3.1% to $29 billion (USRDS, 2011). 
Mortality rates for patients with ESRD have been decreasing slightly due to work by researches, 
focused on improving patient care, but the rates are still very high (> 20% mortality/year in the 
US) and patients in the US receiving dialysis for renal replacement therapy have only a 34% 
survival rate after 5 years on treatment (USRDS, 2011). 
Individuals with CKD, who are not yet at end-stage of the disease, have much better 




expense. If we can identify these individuals earlier in the course of the disease, there is hope 
that many could live without ever having to begin dialysis.  
I feel the next step in trying to incorporate the genetic risk score into patient care 
should be a refinement of the measure, incorporating data from more cohorts. As mentioned, 
the score developed in this project was meant as a proof of concept and it is likely a more 
predictive measure could be created from the 13 SNPs not in linkage disequilibrium with each 
other. A possible refinement that should be more thoroughly explored is the use of weighting 
for each SNP in the score by its effect size. Another option would be to explore the use of 
principal component analysis to reduce the dimension from 13 separate variables in a 
meaningful way.  
After a suitable measure is created, we would need to test it utility, including sensitivity 
and specificity characteristics. This would be a very long term project if we started with a 
population from the general public, as development of CKD does not usually begin until well 
into adulthood. A more plausible study design may be to begin within a nephrology clinic that 
sees some patients who are still in the early stages of the disease and not yet requiring dialysis. 
If they could be genotyped and followed, monitoring their changes in kidney function over 
time, we may find that we can split the patients into those who we’d expect to see a faster 
decline and those who we expect a more gradual decline.  Then one could begin to customize 
treatment options specifically to this expectation and either be more or less aggressive in 




The sample size for this follow-up project would need to be quite large, as there are a 
certain set of individuals who may not be as responsive to normal therapies and who may show 
no benefit. One possible study to approach with this objective is the Chronic Kidney Disease 
Surveillance Project, which is funded by the CDC and run out of the University of Michigan’s 
Kidney Epidemiology and Cost Center 
(http://www.sph.umich.edu/kecc/html/ckdsurveillance.html). This study was funded in order 
to pilot a National Surveillance System for Chronic Kidney Disease in the US. The study uses 
data from combined sources, such as the University of Michigan Health Center and Blue Cross 
Blue Shield of Michigan. Successful feasibility and pilot testing of the proposed system will allow 
the establishment of national CKD surveillance that will likely shape quality improvement, 
promote research and inform health policy related to CKD.  
In summary, work must continue in the area of genetics to help us better understand 
the etiology of chronic diseases and help us shape possible new treatments, in order to 
effectively manage the healthcare of our aging population structure. The findings in this 
dissertation have demonstrated that there are many ways to assess the genetic contributors to 
aging and specific aging-related diseases. Using multi-pronged methods will allow us to assess 
the quality of our findings, and hopefully in the near future, put them into practice to help save 
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